Archive for February, 2018

$ETST Finalizes Human Trial Plans, CBD-Based Formula for Opioid Addiction

DORAL, Fla., Feb. 28, 2018  — via NetworkWire – Earth Science Tech, Inc. (OTC:ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announces that it has finalized the plans for its previously announced human trial to assess the efficacy of the combination of an essential mineral element and full-spectrum cannabinoid industrial hemp oil. The purpose of this nine-month trial is to develop a CBD formulation and methodology for treating opioid addicts, preventing fatal overdoses, and relieving side-effects from withdrawals.

This formulation is expected to increase potency as opposed to the current status quo, which consists solely of essential mineral element therapy (monotherapy) in treating patients with morbid substance abuse and/or dependence.

Globally, there are numerous, promising clinical studies on the potential of cannabinoids for the treatment of substance abuse and psychological disorders. ETST’s new study takes advantage of two of the properties of the Company’s full-spectrum cannabinoids industrial hemp oil that, based on positive feedback from customers and doctors, have demonstrated great success against addiction. ETST’s cannabinoids will be mixed with an essential mineral element, thereby potentially supporting and increasing the action of other drugs and medicinal substances.

The human trial will study substance abuse patients who have undergone drug prescription treatment or dietary supplement monotherapy, full-spectrum cannabinoid monotherapy, and a combination of full-spectrum cannabinoids and a dietary supplement molecule. The patient will receive this treatment sequentially: the first three months with drug prescription treatment monotherapy or dietary supplement monotherapy; the second three months with drug prescription or dietary supplement combined with full-spectrum cannabinoids; and the final three months with full-spectrum cannabinoids.

The project will test the additive nature of full-spectrum cannabinoids with two different forms of an essential mineral element, which will be revealed soon.

Should the potential synergies prove successful, ETST will be positioned to bring innovative new products to the marketplace to counteract the scourge of opioid deaths that is sweeping the United States. ETST intends to produce an over-the-counter nutraceutical product to help addicts resist cravings, as well as a cannabinoid companion for a generic drug to make the treatment more effective while reducing toxicity and adverse side-effects.

ETST Chief Learning Officer Gabriel Aviles and CEO/CSO Dr. Michel Aube, will supervise the project, along with the medical professional advisory board team. The project, along with white paper studies, is expected to be completed by early 2019. This will encourage the Company to pursue clinical studies for at least two years through the remainder of 2019 and 2020, pioneering unprecedented research studies on these two compounds combined.

ETST is currently communicating with its third-party CGMP laboratory on mixing the anti-opioid formula for human trials, and management is in talks with rehab centers interested in participating in the study to some capacity. The Company plans on sharing updates as they progress.

About Earth Science Tech, Inc. (ETST)

Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.

To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com

About Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.EarthSciencePharmaceutical.com

About Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.CannabisThera.com

About KannaBidioiD

KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.KannaBidioiDInc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Dave Demarest
305.546.7640 Office

Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director, Chief Operating Officer
305.615.2118 Office
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Wednesday, February 28th, 2018 Uncategorized Comments Off on $ETST Finalizes Human Trial Plans, CBD-Based Formula for Opioid Addiction

$CIIX Releases Stock Dividend Details

ChineseInvestors.com, Inc. Announces Stock Dividend Details Related to the Spinoff of All Hemp-Related Assets Including its China-based Wholly Owned Foreign Enterprise in, XiBiDi (“CBD”) Biotechnology Co. Ltd. and its Wholly Owned United States Subsidiaries, ChineseHempOil.com, Inc. and Hemp Logic, Inc.

SAN GABRIEL, California, February 28, 2018 —

ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, today announces the details of the stock dividends related to the upcoming spinoff of all hemp-related assets including its China-based wholly owned foreign enterprise, CBD Biotechnology Co. Ltd. (“CBD Biotech”) and its wholly owned United States subsidiaries, ChineseHempOil.com, Inc. (“Chinese Hemp Oil”) and Hemp Logic, Inc. (“Hemp Logic”).

Last month, the Company’s subsidiaries achieved combined sales of over $100,000.00 and are well positioned to continue to achieve substantial growth into 2018 and beyond. CIIX plans to spin off all of its hemp related assets including, but not limited to, CBD Biotech, Chinese Hemp Oil and Hemp Logic into a single private company (the “New Company”) with the goal being to bring the New Company into the public market in 12 to 18 months that follow. The New Company will issue one share of stock in the New Company for every four shares of CIIX’s common stock held by investors as of the date of the spinoff, May 31, 2018.

According to CIIX’s CEO, Warren Wang, “We want to provide our shareholders the opportunity to take advantage of this dividend; therefore, we encourage holders of our preferred stock to convert into common prior to May 31, 2018.”

CIIX will continue to oversee the progress of the New Company. CIIX’s CEO, Mr. Wang, and its CFO, Paul Dickman will serve on the board of directors of the New Company. CIIX is also currently evaluating potential independent board members for the New Company and individuals to join the management team.

CIIX has enjoyed success in helping to support various startup companies through its advertising and public relation related support services. Many of those startup companies have gone on to achieve strong stock prices. We look forward to the Company’s spin off continuing this track record of success. Chinese Hemp Oil, Hemp Logic and CBD Biotech represent the Company’s only involvement in the hemp industry, with its hemp-based CBD products; therefore, spinning off these entities will completely remove the parent, CIIX, from its involvement in the hemp industry, leaving the New Company to capitalize on the continuously growing hemp industry and other complimentary ventures.

“This is a great time to spin off CIIX’s CBD focused assets as we continue to explore new ways to expand its core financial services business, including its recent move into the cryptocurrency and blockchain technology industry,” according to ChineseInvestors.com, Inc.’s CFO Paul Dickman.

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom;

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York
+1-212-418-1217 Office
Editor@NetworkNewsWire.com

Wednesday, February 28th, 2018 Uncategorized Comments Off on $CIIX Releases Stock Dividend Details

$VSQTF Continues Riding Momentum in a Momentous Year

February 27, 2018

  • Stock price increased by more than $3.00 in a two-month period
  • Various acquisitions and partnerships in 2018
  • Focused on incubating the new century’s technology giants

From numerous recent acquisitions to a stock price that has climbed dramatically in the past year, it’s an exciting time for blockchain-focused venture builder Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8).

Engaged in funding and empowering entrepreneurs to implement cutting-edge blockchain solutions, Victory Square is in the business of incubating a new generation of technology titans. The company’s diversified portfolio includes investment interests in the gaming, health care, artificial intelligence and virtual reality sectors, as well as others, and Victory Square’s portfolio companies are effectively disrupting a wide range of sectors across the global economy.

So far in 2018, Victory Square has announced various important acquisitions, including a 100 percent acquisition of established mobile games studio V2 Games Inc. (http://nnw.fm/39sNF), a 31.35 percent acquisition of emerging payment processing company PayVida Solutions Inc. (http://nnw.fm/IE4lM), and a 23.1 percent acquisition of emerging blockchain-focused fintech company Cassia Research Inc. (http://nnw.fm/1t9LV). The company has further forged various exciting strategic partnerships this year.

Victory Square’s stock has enjoyed an impressive boost in a short amount of time, climbing from $0.298 in October 2017 to an impressive $3.32 by December 2017. As of February 27, the company’s price has remained well above $2.00 per share.

Victory Square operates on the idea that impactful companies are built upon experimentation of bold ideas, and entrepreneurs working with the company have invaluable access to Victory Square’s education programs, global mentor network, distribution partners, creative workspaces, operational support and other resources to help them scale on an international level.

The company’s impressive brag sheet includes assisting more than 1,000 entrepreneurs and more than 500 startups to date, helping these entities collectively raise over $100 million and create more than 1,000 jobs.

Victory Square recognizes blockchain as the new major technology and the next key platform for innovation, with the ability to revolutionize the interconnections and operations of business and social structures. Leveraging its extensive expertise and standout prowess in building companies, Victory Square is hard at work identifying, incubating, advising and investing in the industry’s very best blockchain entrepreneurs.

For more information, visit the company’s website at www.VictorySquare.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, February 27th, 2018 Uncategorized Comments Off on $VSQTF Continues Riding Momentum in a Momentous Year

$PVOTF Completes Acquisition of California-Based ERS Holdings, LLC

VANCOUVER, British Columbia, Feb. 27, 2018 —

via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”) is pleased to announce that the Company has completed the acquisition of ERS Holdings, LLC (“ERS”), a privately-held California company. As previously announced on December 20, 2017, ERS has developed a patented technology called “RTIC” Ready-To-Infuse-Cannabis (the “Patent”), relating to the transformation of cannabis oil into powder for infusion into a variety of food and beverage products such as capsules, K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions, and bottled beverages. ERS has also filed several continuation patents that would allow cannabis powder to be combined with other health and wellness products such as natural sleep-aids, cold medications and vitamins.

Invented by Ross Franklin and Ed Rosenthal, the Patent “relates generally to methods and compositions of matter for enabling concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages or food by combining cannabis oil with a starch powder or starch-derived powder.  Embodiments also relate to a variety of culinary uses for the stabilized, emulsified, flavorless concentrated cannabis oil powder.”

Additionally, Mr. Patrick J. Rolfes has been appointed President of ERS Holdings, LLC, a wholly-owned subsidiary of Pivot. Mr. Rolfes will focus on monetizing the intellectual property (“IP”) and has already received expressions of interest from multi-national beer and spirits companies interested in partnering with Pivot to develop and commercialize THC and/or CBD infused branded products. Further, Mr. Ross Franklin, co-inventor of the Patent, has been appointed as ERS’ Director of Research and Development and will continue to invent new and innovative ways to infuse cannabis into foods and beverages.

Alcoholic beverage sales fell by 15 percent following the introduction of medical marijuana laws in a number of US states, according to a new working paper by researchers at the University of Connecticut and Georgia State University. The study also concludes that marijuana availability can reduce alcohol consumption. Another study by Deloitte suggests that “on sales of recreational marijuana alone, the Canadian marketplace could be as much as C$5B per year to start – a number on par with the Canadian spirit market (whiskey, vodka, rum, etc.). At the upper threshold, which takes into account the people who are ‘likely to consume,’ marijuana sales alone could be as high as C$8.7B, similar to sales generated by wine.”

As a consequence, Molson Coors has acknowledged that legal cannabis is a “risk” to their business, stating in their most recent 10-K that  “Although the ultimate impact is currently unknown, the emergence of legal cannabis in certain U.S. states and Canada may result in a shift of discretionary income away from our products or a change in consumer preferences away from beer. As a result, a shift in consumer preferences away from our products or beer or a decline in the consumption of our products could result in a material adverse effect on our business and financial results.”

Dr. Patrick Frankham, CEO of Pivot, stated that “the RTIC family of patents will be transformational for the food and beverage industry. Based on our interaction with key players in the beverage market, we anticipate that there will be a significant substitution in consumer choices towards cannabis infused drinks.  With this acquisition, we have positioned Pivot to be at the forefront of this enormous new market.  Closing this transaction will enable us to further engage interested parties to work with us on developing the full potential of these Patents. Pivot intends to monetize the Patents as quickly as possible and thus I am delighted that Patrick Rolfes and Ross Franklin have joined the Pivot team to accelerate the process.”

Dr. Frankham also stated that “today’s related financing confirms that our vertically integrated cannabis business model is differentiated in the Canadian marketplace and recognized by a strong sponsorship from a sophisticated institutional investor.  The Company will continue working with its financial advisor, Origin Merchant Partners, to successfully close our pending acquisitions and aggressively execute the remainder of our business plan in 2018/2019.”

Convertible Debenture Units

Pivot also announced today a private placement offering of senior secured convertible debentures (“Convertible Debentures”) of the Company with a conversion price of $1.74 per common share for aggregate gross proceeds of $5,000,000 (the “Offering”). The net proceeds received by the Company will be used to, among other things, fund working capital and general corporate purposes, including but not limited to, development of its pipeline of products and intellectual property acquisitions.

The Company has entered into an agreement with an institutional investor with respect to the Offering, whereby the institutional investor has agreed to subscribe for up to $5,000,000 aggregate principal amount of Convertible Debentures. Closing of the Offering is subject to the satisfaction of customary conditions, including the receipt of all requisite regulatory approvals.

The Convertible Debentures will bear interest at the rate of 10% per annum, payable quarterly, will mature 12 months following the date of their issuance and will be convertible at the option of the holder for a period of 12 months into common shares of the Company (“Common Shares”) at a conversion price of $1.74 per Common Share (the “Conversion Price”), subject to adjustment of the Conversion Price in certain events.

Beginning on the date that is four months and one day following the issuance of the Convertible Debentures, the Company may force the conversion of the principal amount of the then outstanding Convertible Debentures at the Conversion Price on not less than 30 days’ notice should the daily volume weighted average trading price of the Common Shares be greater than $2.50 for any 20 consecutive trading days on the Canadian Stock Exchange, or such other exchange as the Common Shares are principally traded.

The Convertible Debentures shall be offered and sold by way of private placement to “accredited investors” within the meaning of NI 45-106 – Prospectus Exemptions and other exempt purchasers (i) in Canada, and (ii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Convertible Debentures or the Company. The Convertible Debentures and the Common Shares issuable upon the conversion of the Convertible Debentures will be subject to a statutory four month and one day hold period.

Subject to the satisfaction of customary of conditions, the Offering is expected to be completed on or about February 28, 2018.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot, ERS, or their respective management, identify forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to accretive earnings, anticipated revenue and costs synergies associated with the acquisition of ERS, statements with respect to internal expectations, estimated margins, expectations for future growing capacity and costs, the completion of any capital project or expansions, the timing for the completion of pending acquisitions, the ability of the Company to complete a financing in order to satisfy its financial obligations under the pending acquisitions and expectations with respect to future production costs. In particular, there can be no assurance that the pending acquisitions will be completed. Forward looking statements are based on certain assumptions regarding ERS, including expected growth, results of operations, performance, industry trends and growth opportunities. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; the possibility that the Company be unable to successfully integrate ERS as described herein; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Any forward-looking statements or facts (including financial information) related to ERS discussed or disclosed herein are derived from information obtained directly from ERS and publicly available sources and has not been independently verified by the Company. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Contact:
Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, February 27th, 2018 Uncategorized Comments Off on $PVOTF Completes Acquisition of California-Based ERS Holdings, LLC

$DJACF CannabisNewsAudio Audio Press Release on Canadian Cannabis Market

New York, New York–(Newsfile Corp. – February 27, 2018) – CannabisNewsAudio announces the Audio Press Release (APR) titled “Key Companies That Will Remap Canada’s Cannabis Retail Industry,” featuring Hiku Brands Company Ltd. (CSE: HIKU) (OTC: DJACF).

To hear the NetworkNewsAudio version, visit: http://nnw.fm/Nm9A2

To read the original editorial, visit: http://nnw.fm/l3Kun

Although the name HIKU is new, the brands behind it are well-known and have interesting back stories. Tokyo Smoke was named “best brand” at the inaugural Cannabis Industry Awards in December 2017, and in January 2018 the company joined forces with Doja Cannabis Company to create HIKU. HIKU is led by CEO Alan Gertner and President Trent Kitsch, who founded the best-selling men’s brand, SAXX Underwear.

The cannabis industry is growing at a rapid pace. While powerful players are teaming up to establish brand presence and formulate creative ways to differentiate themselves, the smaller contenders will begin to get weeded out. With Manitoba’s major retail cannabis players now clear, the stage is set for companies to continue their push toward becoming Canada’s first dominant cannabis retailers. HIKU, with shares trading over $2.50 and an estimated market cap topping $300 million, is definitely one to watch.

About Hiku Brands Company Ltd.

Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop. Hiku’s wholly-owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario. For more information, visit the company’s website at www.Hiku.com

About CannabisNewsWire (CNW)

CannabisNewsWire (“CNW”) is a specialized information service that (1) aggregates cannabis news, (2) provides CannabisNewsBreaks that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information please visit https://wwwCannabisNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://CNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

CNW Corporate Communications Contact:

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Tuesday, February 27th, 2018 Uncategorized Comments Off on $DJACF CannabisNewsAudio Audio Press Release on Canadian Cannabis Market

$CIIX Recognizes Untapped CBD Market for Chinese-Speaking Individuals

February 27, 2018

  • ChineseInvestors.com provides first platform for Chinese-centric CBD market
  • The company boasts real-time services in Chinese character sets
  • ChineseInvestors.com launched CBD navigation application

Founded in 1999, ChineseInvestors.com, Inc. (OTCQB: CIIX) aims to be a leading financial information website that provides real-time market commentary, analysis and education-related services to Chinese-speaking investors through its dynamic financial website, www.Chinesefn.com. ChineseInvestors.com, Inc. went public on the OTCQB Venture Market in January 2012, under the symbol CIIX (http://cnw.fm/RB2Yo).

Having recognized the unprecedented opportunities that lie within the American cannabis industry, the company started laying the foundations to capitalize on the ever-growing demand for cannabidiol-based nutrition and health products. The end of 2016 marked the company’s implementation of plans for its new website, its mobile application and its online distribution of CBD oils for the booming global industry of medical marijuana. Although marijuana use is illegal within the borders of China, cannabis-based oils that include hemp-based CBDs are legal. This unique opportunity opens a potential market of nearly two billion people for the company.

Following the launch of ChineseCBDoil.com in early 2017, the company noted that it was the first online CBD health products store in the Chinese language. The website shows a variety of nutritional supplements containing CBD, including soft gels, capsules and concentrates marketed to Chinese-speaking customers worldwide. It is the company’s intention to open up a retail store in the predominantly Chinese community of San Gabriel, California, which is also where the company’s headquarters is located (http://cnw.fm/0fyWG).

ChineseInvestors.com also launched the world’s first Chinese-language-based mobile cannabis navigation application. This ‘Yelp’ style social media application is set to contain a database of marijuana dispensaries and cannabis strains, along with platforms to review and discuss various cannabis products and maps that show the locations of medical and recreational cannabis dispensaries. Alongside this, the application is set to offer cannabis business summaries and reports from Los Angeles, as well as other large cities, in an effort to provide customers with access to the best recommendations for local marijuana products. The application has been approved by the Apple store and is available for download.

In an effort to assist patients with Alzheimer’s disease, epilepsy, cirrhosis of the liver and a range of other physical and mental ailments, ChineseInvestors.com will continue its focus on investment in both the distribution and the R&D of CBD medicine and health products. With the company’s base of over 100,000 users, alongside its brand value built over the past 18 years, its mission is to become the leading Chinese medical marijuana-focused publicly traded company.

China has nearly 10 million patients that suffer from epilepsy, placing it among the most common diseases that Chinese researchers are eager to cure. Currently, in China, epilepsy cannot be wholly cured, with patients relying heavily on drugs or Chinese herbs to temporarily control the illness. In the United States, epilepsy has been successfully addressed through specialized surgical treatment. However, this option comes with a high risk factor. As a result, a majority of Chinese patients are inclined to seek conservative treatment methods in the field of Western medicine. CBD oil, therefore, has a huge potential within the market space for the treatment of epileptic cases that are located in the mainland or overseas.

Regarding clinical trials and research, ChineseInvestors.com intends to further study the efficacy of CBD oil for the treatment of the above-mentioned illnesses. Apart from that, the company will invest in CBD drug R&D enterprises with the goal of developing various CBD drugs that show positive results when used to combat epilepsy and Alzheimer’s disease. The application period for new drugs of this nature in China is two to four years, which is notably shorter than that of the FDA. It is the company’s goal to be the first company in China to use CBD oil to help mitigate the suffering of patients with epilepsy and Alzheimer’s disease.

The company also offers support services to its various partners, consultative services to smaller private companies that are considering becoming public entities and advertising and public relations-related support services.

With the further legalization of medical marijuana supported by studies, greater market sizes can be expected. With fewer drug side effects and further drug development, it is likely that the number of CBD products will increase, with more people likely to opt for these safer treatments. On a wider scale the problem of acute and chronic pain can be combatted, resulting in fewer production losses in the workplace.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Tuesday, February 27th, 2018 Uncategorized Comments Off on $CIIX Recognizes Untapped CBD Market for Chinese-Speaking Individuals

$NXTD & $DFS Partner to Extend Payments to #IoT Devices, @FitPayInc

Agreement gives Discover cardholders access to the latest payment technology for more secure and convenient contactless payments

RIVERWOODS, Illinois and MELBOURNE, Florida, February 26, 2018 —

Discover Financial Services and FitPay, Inc., a wholly owned subsidiary of NXT-ID, Inc., today announced a network services agreement to allow devices that are integrated with the FitPay Payment Platform[TM] to provision tokenized payment credentials through Discover® Digital Exchange (DDX). The agreement enables Discover cardholders, along with alliance partner cards, to easily make contactless payment transactions at retail locations with wearable or Internet of Things (IoT) devices that include payment capabilities powered by FitPay[TM].

“With the advancements of mobile technology, the way customers interact with merchants is being re-imagined with an eye toward more secure and convenient methods of payment,” said Diane Offereins, Discover’s president of payment services. “This integration with FitPay is one more way in which Discover is continuing to enhance the payment experience and provide more options for our cardholders on how and where they pay.”

Under the agreement, FitPay’s payment and digital wallet platform will be integrated with the Discover tokenization platform, DDX. FitPay’s platform enables manufacturers of IoT and wearable devices to add contactless payment capabilities to their products, making it possible for consumers to pay for goods and services at near field communication (NFC)-enabled point-of-sale terminals with a simple tap. The platform uses tokenization, a payment security technology that replaces cardholders’ account information with a unique digital identifier (“payment token”), to transact more secure contactless payments. The agreement gives Discover cardholders access to the latest contactless payment technology.

“Consumers should have options in how they pay, and this agreement makes cutting-edge payment devices available to Discover cardholders,” said Michael Orlando, COO of NXT-ID and president of FitPay, Inc. “Making payments easy, secure and frictionless requires building an extensive ecosystem. Discover is a unique and important part of that ecosystem, and we are very pleased be able to make the network available to devices on the FitPay Platform.”

Manufacturers of 15 IoT and wearable devices are currently integrating with the FitPay Payment Platform. Product announcements from manufacturers of the devices integrating with the FitPay platform are anticipated in 2018.

About Discover

Discover Financial Services (NYSE: DFS) is a direct banking and payment services company with one of the most recognized brands in U.S. financial services. Since its inception in 1986, the company has become one of the largest card issuers in the United States. The company issues the Discover card, America’s cash rewards pioneer, and offers private student loans, personal loans, home equity loans, checking and savings accounts and certificates of deposit through its direct banking business. It operates the Discover Network, with millions of merchant and cash access locations; PULSE, one of the nation’s leading ATM/debit networks; and Diners Club International, a global payments network with acceptance in more than 185 countries and territories. For more information, visit: http://www.discover.com/company.

NXT- ID, Inc. and FitPay, Inc.

NXT-ID, Inc. (NASDAQ: NXTD) provides a comprehensive platform of technology products and services that enable the Internet of Things (IoT). With extensive experience in access control, biometric and behavior-metric identity verification, security and privacy, encryption and data protection, payments, miniaturization and sensor technologies, NXT-ID develops and markets groundbreaking solutions for payment and IoT applications. Its industry-leading technology products and solutions include MobileBio®, a suite of biometric solutions that secure consumers’ mobile platforms, the Wocket™, a next-generation smart wallet and the Flye, a digital credit card developed in collaboration with WorldVentures. NXT-ID includes three mobile and IoT-related subsidiaries: LogicMark, LLC, a manufacturer and distributor of non-monitored and monitored personal emergency response systems (“PERS”) sold through dealers/distributors and the United States Department of Veterans Affairs; FitPay, Inc., a proprietary technology platform that delivers end-to-end solutions to device manufacturers for contactless payment capabilities, credential management, authentication and other secure services within the IoT ecosystem, and 3D-ID LLC, which is engaged in biometric identification and authentication. Learn more about NXT-ID at http://www.nxt-id.com. NXT-ID Inc. Corporate Contact: info@nxt-id.com. FitPay and the FitPay Payment Platform are trademarks of FitPay, Inc.

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

Media Contacts:
Chris Orlando
FitPay, Inc.
chris@fit-pay.com
760-468-7273

Jeremy Borling
Discover
jeremyborling@discover.com
224-405-4252
@Discover_News

Monday, February 26th, 2018 Uncategorized Comments Off on $NXTD & $DFS Partner to Extend Payments to #IoT Devices, @FitPayInc

$DJACF CannabisNewsWire Publication on Cannabis Innovators, Canadian Retail Industry

February 23, 2018

CannabisNewsWire Editorial Coverage: Out of 120 applicants, Manitoba recently awarded four master retail licenses, a monumental action as Canada prepares to legalize cannabis for recreational use this summer. The entities that now hold prized licenses to retail pot and its associated paraphernalia in the province are: Tokyo Smoke, a subsidiary of HIKU Brands (CSE:HIKU; OTCBB: DJACF) (DJACF Profile); a consortium of Delta 9 Cannabis Inc. and Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF); National Access Cannabis (CSE: NAC) (OTC: NACNF); and 10552763 Canada Corporation. One key industry player that missed out on this licensing opportunity is MedReleaf (TSE: LEAF) (OTC: MEDFF). These licenses open the doors to considerable recreational retail revenue potential, and investors with foresight were quick to take action, with Aphria (TSX: APH) (OTC: APHQF) and Koicha Partners LP investing millions into the big four’s newest presence, HIKU.

New name, established brand

Although the name HIKU is new, the brands behind it are well-known and have interesting back stories. Tokyo Smoke was named “best brand” at the inaugural Cannabis Industry Awards in December 2017, and in January 2018 the company joined forces with Doja Cannabis Company to create HIKU. HIKU is led by CEO Alan Gertner and President Trent Kitsch, who founded the best-selling men’s brand, SAXX Underwear.

Gertner ran a $100 million business as head of an Asia-Pacific-wide sales team during his tenure in corporate strategy at Google. When he found that what he thought was his dream job was less than fulfilling, he shifted gears and co-founded Tokyo Smoke with his father Lorne Gertner, formerly PharmaCan chairman (now Cronos Group), who was dubbed the ‘Godfather of Canadian Cannabis’.

Tokyo Smoke is a seasoned retailer, already running stores online and several successful brick-and -mortar shops, selling a range of experiential products that feature the creative use of cannabis. Established already in key markets like Toronto and Calgary, Tokyo Smoke’s cannabis will soon be on shelves in legal recreational dispensaries in the United States.

East meets West in merging of cannabis retail and production minds

Partnering with Doja Cannabis, a seasoned Kelowna-based pot producer, was Gertner’s first foray into production. The strategy of merging minds with industry expertise in producing and retailing pot brought Gertner, based in the east, and Kitsch, based in the west, to a new market in the Manitoban middle ground.

The cannabis industry is growing at a rapid pace. While powerful players are teaming up to establish brand presence and formulate creative ways to differentiate themselves, the smaller contenders will begin to get weeded out. With Manitoba’s major retail cannabis players now clear, the stage is set for companies to continue their push toward becoming Canada’s first dominant cannabis retailers. HIKU, with shares trading over $2.50 and an estimated market cap topping $300 million, is definitely one to watch.

Comparables:

Aphria (NASDAQ: APHQF) (TSE: APH) was founded in 2011 and is headquartered in Leamington, Ontario. The company calls itself one of the lowest-cost producers of marijuana, and produces dry cannabis, as well as cannabis oil of varying qualities and strength. Its cannabis is 100 percent greenhouse grown. Aphria’s estimated market cap is over $2 billion.

Canada’s largest producer, Canopy Growth (OTC: TWMJF) (TSE: WEED), has a market cap of more than $4 billion, with shares currently trading over $22, a 61.3% increase over the last three months.  Formerly known as Tweed Marijuana Inc., Canopy Growth was founded by Bruce Linton in 2014, and is based in Smiths Falls, Ontario. Canopy Growth is the first federally regulated, publicly traded cannabis producer in North America. It operates numerous production facilities across Canada and around the world with over 700,000 square feet of production licensed under Canada’s medical cannabis framework.

National Access Cannabis (OTC: NACNF) (CSE: NAC) National Access Cannabis’ market cap is over $135 million; stock is trading over $1. The company operates medical cannabis care centers across Canada, National Access is adapting its established medical clinic model to meet the needs of the Manitoba retail market.  National Access works alongside Health Canada and Licensed Producers to help qualifying patients gain access to their license. After receiving the Manitoba retail National Access announced it intends to deepen its relationships with CannaRoyalty Corp. and Cannabis Wheaton Income Corp.

MedReleaf (TSE: LEAF) (OTC: MEDFF) was voted Top Licensed Producer at the Lift Canadian Cannabis Awards.  MedReleaf is an Ontario- based, R&D-driven company dedicated to innovation, and delivering products to the global medical market, and providing brands and product assortment for the recreational consumer market. MedReleaf’s market cap is currently over $2.26 billion.

For a more in-depth look into HIKU Brands, visit HIKU Brands (CSE:HIKU; OTCBB: DJACF) or read the FULL Report: Cannabis Investors Need Three M’s To Success: Money, Moxie, and Management

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Monday, February 26th, 2018 Uncategorized Comments Off on $DJACF CannabisNewsWire Publication on Cannabis Innovators, Canadian Retail Industry

$PBIO to Create Unique Analytical System Using Patented Pressure Cycling Technology

February 21, 2018

  • The two companies entered co-marketing and distribution agreement to be implemented worldwide
  • Pressure BioSciences’ high pressure generator technology can improve optical spectroscopy accuracy and data collection with potentially far-reaching impact on drug development
  • The joint technology will be promoted to scientists all over the world and is expected to generate increased sales starting this year

A leading developer and provider of innovative high pressure-based solutions to the global life sciences industry, Pressure BioSciences, Inc. (OTCQB: PBIO) has entered a two-year agreement with ISS, Inc., a prominent designer and manufacturer of advanced scientific instruments with more than 30 years of experience in the field. Under the agreement, the two companies will join their marketing and distribution efforts worldwide, as well as their own technologies to create an advanced high pressure optical spectroscopy system that’s expected to generate significant data that could be critical to the discovery and development of new biopharmaceutical diagnostics and drugs, according to a Pressure BioSciences press release issued on February 14, 2018 (http://nnw.fm/zf2UE).

Optical spectroscopy is typically used by scientists all over the world as a powerful analytical method to generate and gather information about the composition of biological molecules. The collected data have multiple applications ranging from the design of new drugs to the development of preventive strategies against certain diseases. However, with high pressure optical spectroscopy, scientists have access to a more unique and effective way to study molecular interactions instantaneously and with a better control of reversibility and irreversibility, due to the easily adjustable duration and amount of applied pressure. This can greatly improve the speed and accuracy of data collection, helping scientists better understand how biological molecules function and interact, with a significant impact on the discovery and development of improved drugs and diagnostics.

ISS is confident that, by using Pressure BioSciences’ patented and game-changing pressure cycling technology (“PCT”) with its optical cell systems instead of current manual pressure generators, scientists will be able to “visualize biochemical reactions as they are happening in the pressure cell,” as noted by ISS President Dr. Ben Barbieri in a news release. “The Pressure BioSciences pressure generators will also facilitate automated and significantly faster data collection. Such systems could potentially have a significant and far-reaching impact on drug development and other important areas of biomedical research worldwide,” he added.

“This powerful combination of technologies will be promoted to scientists worldwide by both Pressure BioSciences and ISS, with the combined system expected to drive an increase in sales this year and beyond,” commented Dr. Nate Lawrence, PBIO VP of Marketing and Sales.

The ISS Agreement is the latest in a series of acquisitions and collaborations that Pressure BioSciences has entered into over the last few months, including, most notably, the acquisition of BaroFold, Inc.’s assets in December of last year and its entry into a strategic partnership with Phasex Corporation in October 2017. The BaroFold acquisition has significantly increased the company’s intellectual property estate by eight issued patents and several others that are pending, as noted by CEO Richard T. Schumacher on a ‘Stock Day’ podcast (http://nnw.fm/E65rm).

With Phasex, the collaboration has allowed Pressure BioSciences to enter the fast-growing nanoemulsions market, where its proprietary PCT-based Ultra Shear Technology can be used with Phasex’s Supercritical Fluid processing to generate water-soluble, fully stable nanoemulsions. Ensuring stability of nanoemulsions has been a challenge until now, but this strategic collaboration has every chance to change that, leading to the further expansion of an already large market and an increase in the number of potential nanoemulsion applications in industries ranging from pharmaceuticals, nutraceuticals, cosmetics, paints and industrial lubricants to food and even medical cannabis (e.g., CBD).

Unlike most commercially-available emulsions, which tend to be unstable and sometimes inappropriate for human use due to a high amount of surfactants required, nanoemulsions have been shown to improve absorption, enhance stability, exhibit higher bioavailability, contain reduced amounts of surfactants and present multiple other advantages. Pressure BioSciences is confident that, with its patented Ultra Shear Technology, it will be able to develop commercial-scale nanoemulsions that require less emulsifying events, or even none at all.

For more information, visit the company’s website at www.PressureBioSciences.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, February 26th, 2018 Uncategorized Comments Off on $PBIO to Create Unique Analytical System Using Patented Pressure Cycling Technology

$ETST Focuses on Completing Key Projects in 2018 – CannabisNewsBreaks

February 7, 2018

  • Goal is to raise $4 million to help company finance its planned projects
  • Expansion into Canada eyed, attorney retained to help seek Canadian licenses to import ETST’s CBD-rich hemp oil into country
  • ETST would also use funding for MSN-2, its home kit for the detection of sexually transmitted diseases

Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://cnw.fm/W8I2d). The funds would be used to finance its planned projects in the new year and for general working capital (http://cnw.fm/Pi0hl), with share cancellation by company founders counteracting dilution.

ETST is also eyeing expansion into Canada in 2018, and it has appointed an attorney who will serve as consultant for ETST’s activities in that country, Avi Levi, Esq. (http://cnw.fm/aW8ww). He will help the company apply for licenses to import its CBD-rich hemp oil into Canada. It will then be exported to various countries as raw hemp oil or in individual ready-to-consume bottles, the company said.

Dr. Michel Aube, CEO and chief scientific officer of the company, said, “With the funds being raised through the Regulation A+ offering, we will be in a position to begin finalizing all of our projects while we pursue grants from the Canadian government to cover our MSN-2 medical device, CBD patent pending formulas and CBD based generic pharmaceutical drugs.”

The MSN-2 device is prepared for third-party evaluation ahead of manufacture and commercialization. The MSN-2 device is a home kit designed for the detection of sexually transmitted diseases.

ETST is a biotechnology company operating in the fields of hemp cannabinoid pharmaceutical, nutraceutical, and medical device R&D. Its hemp CBD is made using the liquid extraction process. As a result, its CBD oil is 100 percent natural and organic, as noted by the company.

ETST has three wholly owned subsidiaries. First, Earth Science Pharma, Inc. specializes in the development of medical devices for the treatment of sexually transmitted diseases. Second, Cannabis Therapeutics, Inc. works to explore the medicinal powers of CBD. Cannabis Therapeutics holds a provisional application patent for a CBD product which develops treatments for ovarian and breast cancers. Third, KannaBidioid, Inc. focuses on the recreational cannabis space.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Monday, February 26th, 2018 Uncategorized Comments Off on $ETST Focuses on Completing Key Projects in 2018 – CannabisNewsBreaks

$PVOTF Advances #CBD Therapy Delivery Options

February 26, 2018

  • Forecasts envision medical cannabis market reaching $55.8 billion by 2025
  • PVOTF filing patents for smoked, transdermal and mucosal delivery of therapeutics
  • Global partnerships and acquisitions open windows of opportunity for company

With its recently announced plan to acquire Agro-Biotech, a Québec-based ACMPR Canadian licensed cannabis producer (http://cnw.fm/WPwl2), Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) has raised the bar in the race to capture part of the booming medical cannabis market, which is expected to reach over $55 billion by 2025. Agro-Biotech, which operates a fully-licensed indoor hydroponic cannabis production facility that’s able to turn out 10,000 kilograms per year, gives Pivot Pharmaceuticals a unique vertically-integrated position in the industry. Pivot is already known for its advanced patent-backed CBD therapy delivery options, and delivery technology has become a hot button in the burgeoning marijuana market.

Amid the flurry of activity surrounding the rush to provide medical marijuana therapies in markets where it is newly legalized, one lingering question regulators and industry insiders continue to grapple with is how to best administer cannabis to patients seeking relief from muscle spasms, pain, anxiety and other disorders. Pivot Pharmaceuticals is evaluating and preparing to market a variety of drug delivery technologies that can help the assimilation of cannabinoids for such human and veterinary patients.

Pivot has identified an area of need within the industry as efforts to provide clinical data for cannabis’s purported benefits strive to establish a scientific credence to what has been a largely word-of-mouth substantiation of the drug. Decades of recreational use, mostly in smoking marijuana, as well as historical research into cannabis’s ancient therapeutic uses, have given rise to the newly popular movement to establish clinical uses for the plant as governmental recognition has spread across the United States and Canada, as well as in some other countries across the globe.

As part of that movement, some companies are searching for alternatives to smoking the plant, not only to avoid the image of casual and medically unregulated recreational drug use but also out of concern for patients’ health and the interests of non-patients who may be offended by the smoke. Pivot has filed three provisional patents targeting different cannabinoid delivery methods. One anticipates inhalation for delivery of the therapeutics, another promotes transdermal passage through the skin using patches and creams, and a third prefers topical delivery through mucus in the buccal, nasal, vaginal and anal areas using a gel, mouthwash or suppository (http://cnw.fm/qT4N3).

The British Columbia, Canada-based company’s agreement with Germany’s Solmic Research GmbH has given Pivot worldwide rights to the Solmic Solubilisation technology underpinning a water-soluble oral solution that Pivot has made ready for market. A partnership with Israel’s Solubest Ltd. has resulted in a semi-solid cream that is currently in the stability evaluation phase of development, and Pivot’s anticipated February 28 closing on its option to acquire 100 percent of North Carolina’s Thrudermic, LLC has already led to the commencement of development of a product using Thrudermic’s transdermal nanotechnology for a systemic cannabidiol (CBD) product. Access to Israeli labs licensed to work with CBD and its more intoxicating cannabis sibling tetrahydrocannabinol (THC) gives Pivot an edge in research and development.

Pivot is also scheduled to close on its acquisition of California’s ERS Holdings, LLC on February 28, which has a patented ready-to-infuse cannabis (“RTIC”) oil-to-powder technology that Pivot expects to monetize by entering the cannabis-infused beverage market, particularly in the alcohol beverage industry, where Pivot has already identified potential partners as beverage companies battle the possibility of legal marijuana eating into beer sales (http://cnw.fm/AdR47). The company also expects to use RTIC technology for wellness products such as over-the-counter sleep aids and cough medications.

As legalization has spread for cannabis’s medical applications, market forecasts have grown, and the therapeutic product derivatives of the plant are expected to fuel a $55.8 billion market by 2025, according to a 2017 report by Grand View Research (http://cnw.fm/98vNG). Pivot’s first Solmic-enabled oral product, PGS-N001, is designed to provide relief to patients suffering from chemotherapy-induced vomiting, nausea, neutropenia and anemia — major side effects from cancer treatment that often lead to the premature discontinuation of the treatment. Of the 14 million new cancer diagnoses identified by the National Cancer Institute in 2012, about four million of them were expected to lead to chemotherapy treatment, and chemotherapy-induced nausea and vomiting (“CINV”) affects an estimated 70 to 80 percent of patients undergoing chemotherapy, according to Transparency Market Research (http://cnw.fm/8RC0y), fueling a cancer supportive care products market that’s expected to reach $29.87 billion by 2021.

Pivot intends to register PGS-N001 as a natural health product for consumers and follow it with other products that will have a shorter development cycle as they follow the natural health product pathway.

“Solmic’s water-soluble technology has already been demonstrated in the nutraceutical and cosmeceutical markets in Europe,” Pivot CEO Patrick Frankham stated in a news release. “The addition of Solmic, our second disruptive drug delivery technology platform for cannabinoids, strengthens our business strategy to be a market leader in the development and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.”

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Monday, February 26th, 2018 Uncategorized Comments Off on $PVOTF Advances #CBD Therapy Delivery Options

$DJACF Among the Key Companies That Will Remap Canada’s Cannabis Retail Industry

February 23, 2018

CannabisNewsWire Editorial Coverage: Out of 120 applicants, Manitoba recently awarded four master retail licenses, a monumental action as Canada prepares to legalize cannabis for recreational use this summer. The entities that now hold prized licenses to retail pot and its associated paraphernalia in the province are: Tokyo Smoke, a subsidiary of HIKU Brands (CSE:HIKU; OTCBB: DJACF) (DJACF Profile); a consortium of Delta 9 Cannabis Inc. and Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF); National Access Cannabis (CSE: NAC) (OTC: NACNF); and 10552763 Canada Corporation. One key industry player that missed out on this licensing opportunity is MedReleaf (TSE: LEAF) (OTC: MEDFF). These licenses open the doors to considerable recreational retail revenue potential, and investors with foresight were quick to take action, with Aphria (TSX: APH) (OTC: APHQF) and Koicha Partners LP investing millions into the big four’s newest presence, HIKU.

New name, established brand

Although the name HIKU is new, the brands behind it are well-known and have interesting back stories. Tokyo Smoke was named “best brand” at the inaugural Cannabis Industry Awards in December 2017, and in January 2018 the company joined forces with Doja Cannabis Company to create HIKU. HIKU is led by CEO Alan Gertner and President Trent Kitsch, who founded the best-selling men’s brand, SAXX Underwear.

Gertner ran a $100 million business as head of an Asia-Pacific-wide sales team during his tenure in corporate strategy at Google. When he found that what he thought was his dream job was less than fulfilling, he shifted gears and co-founded Tokyo Smoke with his father Lorne Gertner, formerly PharmaCan chairman (now Cronos Group), who was dubbed the ‘Godfather of Canadian Cannabis’.

Tokyo Smoke is a seasoned retailer, already running stores online and several successful brick-and -mortar shops, selling a range of experiential products that feature the creative use of cannabis. Established already in key markets like Toronto and Calgary, Tokyo Smoke’s cannabis will soon be on shelves in legal recreational dispensaries in the United States.

East meets West in merging of cannabis retail and production minds

Partnering with Doja Cannabis, a seasoned Kelowna-based pot producer, was Gertner’s first foray into production. The strategy of merging minds with industry expertise in producing and retailing pot brought Gertner, based in the east, and Kitsch, based in the west, to a new market in the Manitoban middle ground.

The cannabis industry is growing at a rapid pace. While powerful players are teaming up to establish brand presence and formulate creative ways to differentiate themselves, the smaller contenders will begin to get weeded out. With Manitoba’s major retail cannabis players now clear, the stage is set for companies to continue their push toward becoming Canada’s first dominant cannabis retailers. HIKU, with shares trading over $2.50 and an estimated market cap topping $300 million, is definitely one to watch.

Comparables:

Aphria (NASDAQ: APHQF) (TSE: APH) was founded in 2011 and is headquartered in Leamington, Ontario. The company calls itself one of the lowest-cost producers of marijuana, and produces dry cannabis, as well as cannabis oil of varying qualities and strength. Its cannabis is 100 percent greenhouse grown. Aphria’s estimated market cap is over $2 billion.

Canada’s largest producer, Canopy Growth (OTC: TWMJF) (TSE: WEED), has a market cap of more than $4 billion, with shares currently trading over $22, a 61.3% increase over the last three months.  Formerly known as Tweed Marijuana Inc., Canopy Growth was founded by Bruce Linton in 2014, and is based in Smiths Falls, Ontario. Canopy Growth is the first federally regulated, publicly traded cannabis producer in North America. It operates numerous production facilities across Canada and around the world with over 700,000 square feet of production licensed under Canada’s medical cannabis framework.

National Access Cannabis (OTC: NACNF) (CSE: NAC) National Access Cannabis’ market cap is over $135 million; stock is trading over $1. The company operates medical cannabis care centers across Canada, National Access is adapting its established medical clinic model to meet the needs of the Manitoba retail market.  National Access works alongside Health Canada and Licensed Producers to help qualifying patients gain access to their license. After receiving the Manitoba retail National Access announced it intends to deepen its relationships with CannaRoyalty Corp. and Cannabis Wheaton Income Corp.

MedReleaf (TSE: LEAF) (OTC: MEDFF) was voted Top Licensed Producer at the Lift Canadian Cannabis Awards.  MedReleaf is an Ontario- based, R&D-driven company dedicated to innovation, and delivering products to the global medical market, and providing brands and product assortment for the recreational consumer market. MedReleaf’s market cap is currently over $2.26 billion.

For a more in-depth look into HIKU Brands, visit HIKU Brands (CSE:HIKU; OTCBB: DJACF) or read the FULL Report: Cannabis Investors Need Three M’s To Success: Money, Moxie, and Management

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Friday, February 23rd, 2018 Uncategorized Comments Off on $DJACF Among the Key Companies That Will Remap Canada’s Cannabis Retail Industry

$VSQTF Pursuing Opportunities to Leverage Blockchain, NetworkNewsAudio Audio Press Release

New York, New York–(Newsfile Corp. – February 23, 2018) – NetworkNewsAudio announces the Audio Press Release (APR) titled “Five Blockchain Companies to Watch in 2018,” featuring Victory Square Technologies, Inc. (CSE: VST) (OTC: VSQTF) (FWB: 6F6).

To hear the NetworkNewsAudio version, visit: http://nnw.fm/xH95v

To read the original editorial, visit: http://nnw.fm/ALGc8

In December 2017, Victory Square Technologies joined the Blockchain Investors Consortium (“BIC”), an influential group with more than $2 billion of digital assets. BIC pools member experience and expertise in shared due diligence efforts to identify investment opportunities in the most promising and disruptive blockchain-enabled companies.

The membership enabled a pathway for Victory Square Technologies to take an early-mover position in the Initial Coin Offering (“ICO”) rush via participation in Bluzelle’s (“BLZ”) early contributor round token sale (http://nnw.fm/8kxfC). With the purchase of a $250,000 allocation of BLZ tokens, Victory Square also received 25 percent more tokens for its contribution.

Victory Square also retained Bluzelle CEO Pavel Bains as a strategic advisor to help advance Victory Square’s Blockchain Assembly portfolio company, leveraging his expertise in blockchain and fintech, including ICOs and tokens.

About Victory Square Technologies Inc.

Victory Square is a venture builder that creates, funds and empowers entrepreneurs predominantly focused on blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources and other forms of operational support to help them scale internationally. For more information, visit www.VictorySquare.com.

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, February 23rd, 2018 Uncategorized Comments Off on $VSQTF Pursuing Opportunities to Leverage Blockchain, NetworkNewsAudio Audio Press Release

$ETST European Industrial Hemp and Mr. Checkout Could be Key Players in 2018

February 23, 2018

  • ETST projects a breakout year in 2018 from its new line of High Grade Full Spectrum Cannabinoids, marketed as a cannabinoid complex
  • Checkout sells to major retailers, such as Walmart and Target, as well as a network of independent distributors and retail owners
  • ETST’s new line is sourced from European industrial hemp, but it is mixed, bottled and packaged in the U.S.

Earth Science Tech, Inc. (OTC: ETST) is projecting a breakout year in 2018, resetting its executive team and implementing a new marketing strategy. Playing key roles in the predictions of higher volume and performance are new Netherlands-sourced industrial hemp-based products and Mr. Checkout, the specialty distributor that focuses on retail placement (http://nnw.fm/1NpT6).

The company recently launched its revamped and repackaged line of industrial hemp products as a cannabinoid complex. It uses a CO2 extraction process with organically grown and unfiltered industrial hemp. It sources the product from Europe, but it is mixed, bottled and packaged in the U.S. The European Industrial Hemp Association (EIHA) is working with the World Health Organization (WHO) for a product review, and its next meeting is set for May 2018 (http://nnw.fm/6AL1f).

ETST is an innovative biotech company based in Doral, Florida. Its new line consists of High Grade Full Spectrum Cannabinoids product. It is focused on the cannabinoid, nutraceutical and pharmaceutical fields, and it also conducts R&D for certain medical devices. The new cannabinoid complex line is unique, because it offers the user a specific disclosure of the milligrams (mg) of each cannabinoid. The cannabinoid complex is rich in Terpenes and Saponins, ETST said.

Mr. Checkout, a distributor originally launched in 1989, specializes in distribution to major retailers, such as Walmart, Target and Walgreens, and it also to a network of 1,100 independent distributors and 50,000 independent retail owners within a national network in the U.S. It also offers comprehensive logistics expertise in shipping and boasts a ‘Fast Track’ program designed to get product onto retail shelves quickly (http://nnw.fm/kbLY2).

ETST markets a 100 percent natural and organic high grade hemp cannabidiol and holds three wholly-owned subsidiaries: Earth Science Pharmaceutical has a line of low-cost, non-invasive medical devices for the detection of sexually transmitted diseases (STDs); Cannabis Therapeutics is an emerging biotechnology company; and KannaBidioilD is targeted to the recreational market.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Friday, February 23rd, 2018 Uncategorized Comments Off on $ETST European Industrial Hemp and Mr. Checkout Could be Key Players in 2018

$PVOTF “Seed to Derivatives” – Vertical Integration in Burgeoning Cannabis Market

February 23, 2018

  • Letter of Intent to acquire Agro-Biotech, to become vertically integrated from “seed to derivatives”
  • Development and commercialization of therapeutic pharmaceuticals and nutraceuticals
  • Patented formulation and delivery technologies

Scientific studies have provided empirical credence to the medical efficacy of cannabinoids for multiple maladies. Globally, researchers and biopharmaceutical companies are now laser focused on cannabinoid-based therapeutics that may hold blockbuster medical potential, providing solutions to a range of unmet medical needs. However, current drug delivery techniques remain antiquated. There are inherent metabolic and bioavailability issues affecting the consistent, effective delivery of cannabinoids. It’s becoming clear that these new pharmaceutical therapeutics require revolutionary delivery techniques.  Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) is establishing new paradigms in cannabinoid drug development and delivery.

Pivot Pharmaceuticals is transforming the development and commercialization of these new therapeutic pharmaceuticals and nutraceuticals with unique drug delivery platform technologies. Pivot’s medical cannabis product division, Pivot Green Stream Health Solutions (PGS), conducts research, development, and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals, and it has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical) and Solmic Solubilisation technology (oral) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. The company recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office (http://cnw.fm/2e8HS), and these latest patent filings join an established number of global rights to topical, oral, transdermal, food and beverage technologies that Pivot has already secured.

Pivot’s pipeline of potential CBD-based pharmaceuticals now covers treatment indications for supportive care to relieve nausea, mucositis and pain, including cancer-related and menstrual pain, dermatological conditions and even glaucoma. Pivot is also developing and commercializing an array of pharmaceutical-grade formulations for cannabinoid-based consumer health care products.

With enhanced drug delivery and development well underway, Pivot has turned to its next business objective, vertical integration. The company just announced a Letter of Intent for the proposed acquisition of Agro-Biotech, a Québec-based ACMPR Canadian licensed cannabis producer (http://cnw.fm/rGD5M). Agro-Biotech operates a fully licensed, purpose-built, indoor hydroponic cannabis production facility capable of producing a cumulative 10,000 kilograms per year.

Pivot is already a differentiated player in the Canadian cannabis industry due to its unique approach to enhanced dosing and bioavailability of cannabinoids with proven pharmaceutical and patented formulation and delivery systems. With the acquisition of Agro-Biotech, Pivot Pharmaceuticals expects to become vertically integrated, controlling the entire manufacturing process from “seed to derivatives” and capturing margin along the entire supply chain.

In the news release, Dr. Patrick Frankham, Pivot CEO, stated, “I am delighted to welcome Agro-Biotech to Pivot…  With this acquisition, we are well positioned to enter the Québec cannabis market and attract experienced scientists to our organization.  Pivot will seek to expand its footprint in the province beginning immediately following financing activities which are underway.  After several months of identifying and discussing with potential partners in the cannabis space, the Pivot management team and our scientific advisors agreed that it was in the best interest of our shareholders to acquire the compliment of licenses which will enable us to develop our pipeline of patented formulation and delivery technologies all under one vertically integrated process from seed to derivatives.  Pivot will only work with partners who truly control their processes and have the finest infrastructure and qualified personnel.  We believe that these characteristics will define best in class products for wellness and health conscious consumers using bio-cannabis….”

This latest announcement follows a pattern of strong corporate development by Pivot Pharmaceuticals and uniquely positons the company to become a major force in the burgeoning cannabis markets not only in Canada but around the world.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Friday, February 23rd, 2018 Uncategorized Comments Off on $PVOTF “Seed to Derivatives” – Vertical Integration in Burgeoning Cannabis Market

$NETE Joins the Enterprise Ethereum Alliance – NetworkNewsBreaks

Prestigious Enterprise Ethereum Alliance welcomes Net Element to its network of innovative companies 

MIAMI, FL, Feb. 21, 2018 — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group, today announces that it has joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative with over 250 member companies. Net Element’s membership to the prestigious alliance is complementary to the Company’s recently announced decentralized blockchain technology solution that will enable an unlimited number of value-added services (“VAS”) and support the adoption of Ethereum in the enterprise.

The EEA seeks to augment Ethereum adoption as an enterprise-grade technology, with research and development focused on privacy, confidentiality, scalability and security.  Net Element is developing a decentralized crypto-based ecosystem to act as a framework for a number of value-added services that can connect merchants and consumers directly, via blockchain technology, while increasing the economic efficiency of all transactions conducted within the ecosystem.

Part of this initiative is the Company’s recently launched Netevia platform which delivers end-to-end multi-channel payment processing through easy-to-use APIs, point-of-sale (“POS”), e-commerce and mobile devices.  Netevia’s blockchain solution, code-named “VIA Protocol,” is currently under development and is intended to enable new billing methodologies over the blockchain as well as create dynamic service offerings such as rewards, loyalty and one-click payments.

“EEA’s rapid growth in membership mirrors the accelerating acceptance and deployment of Ethereum blockchain solutions in the global marketplace,” says Julio Faura, EEA’s chairman of the board. “The technological breadth, depth and variety of organizations coming together under the auspices of EEA to create and drive enterprise Ethereum standards bodes well for the future development of the next-generation Ethereum ecosystem.”

“We are excited to be a part of the Ethereum Alliance, which connects Fortune 500 enterprises, startups, academics and technology vendors with Ethereum subject matter experts,” comments Net Element CEO Oleg Firer. “We look forward to leveraging the EEA network as we build more value for our community by developing our blockchain ecosystem for value-added services.”

“Net Element is focused on delivering value-added solutions for our community as we develop decentralized blockchain solutions to connect merchants and consumers. Alongside leading global enterprises, such as Microsoft, Intel, JPMorgan, Samsung, ING, MasterCard, Thomson Reuters, Cisco Systems, and others, we have partnered with EEA to establish clear roadmap, robust governance model, and useful Ethereum resources.”

About The Enterprise Ethereum Alliance
The EEA is an industry-supported, not-for-profit established to build, promote, and broadly support Ethereum-based technology best practices, open standards, and open-source reference architectures. The EEA is helping to evolve Ethereum into an enterprise-grade technology, providing research and development in a range of areas, including privacy, confidentiality, scalability, and security. The EEA is also investigating hybrid architectures that span both permissioned and public Ethereum networks as well as industry-specific application layer working groups.

EEA will collectively develop open industry standards and facilitate collaboration with its member base and is open to any members of the Ethereum community who wish to participate. This open-source framework will enable the mass adoption at a depth and breadth otherwise unachievable in individual corporate silos and provide insight to the future of scalability, privacy, and confidentiality of the public Ethereum permissionless network. Further information is available at www.entethalliance.org.

About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S. it aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, our cloud based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™.  In 2017 we were recognized by South Florida Business Journal’s as one of 2016’s fastest growing technology companies. Further information is available at www.netelement.com.

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to the timing of completion of new features for the Netevia platform, whether contemplated projects and the utilization of blockchain technology will be successful, whether the addition of blockchain technology-focused payment processing solutions business will become a framework for multiple value-added services, whether the Company will be successful in expansion and growth endeavors; and even if it is successful in any or all of these endeavors, whether this will positively impact the Company or result in improved shareholder value. Additional examples of such risks and uncertainties are: (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Net Element, Inc.
1-786-923-0502
media@netelement.com
Thursday, February 22nd, 2018 Uncategorized Comments Off on $NETE Joins the Enterprise Ethereum Alliance – NetworkNewsBreaks

$VSQTF to Enter Definitive Agreements to Acquire 28.5% of Howyl Ventures

VANCOUVER, British Columbia, Feb. 22, 2018  — Subject to all requisite regulatory approvals, Victory Square Technologies Inc. (“Victory Square” or the (“Company”) (CSE:VST)(OTC:VSQTF)(FWB:6F6) will acquire 28.5% of all issued and outstanding shares of Howyl Ventures Inc. (“Howyl”), and their decentralized project marketplace platform, Capaciti, for $1,000,000 CAD in total consideration (the “Purchase Price”).

Pursuant to definitive share purchase and subscription agreements to be executed between the Company and the shareholders of Howyl (the “Share Purchase Agreement”), and the Company and Howyl (the “Subscription Agreement”), respectively, the aggregate Purchase Price will be paid and satisfied by the Company through cash installments totalling $100,000 (the “Cash Consideration”) by the Company and the issuance of 364,372 common shares in the capital of the Company (the “Consideration Shares”) to the shareholder(s) of Howyl at a deemed issue price of $2.47 per Consideration Share. The deemed issue price represents the closing price of the common shares of the Company on the Canadian Securities Exchange at the end of trading on February 21, 2018, the trading day preceding this news release announcing this acquisition, less a discount of 10%. In accordance with the terms of the Share Purchase Agreement, the Consideration Shares shall be subject to resale restrictions, which permit 8% of the Consideration Shares to be eligible to be free-trading four months from the date of issuance to satisfy the statutory hold period and a further 8% every three months thereafter until the final balance of Consideration Shares is eligible to be free-trading in approximately three years’ time. The Share Purchase Agreement and Subscription Agreement also contain standard representations, warranties and covenants for transactions of this nature.

Capaciti will be the first enterprise-grade, decentralized project marketplace in the world. Its technology will fully complement the massive growth in digital freelancing, being driven by a convergence of connectivity, distributed skilled workers, a shift to output-oriented work, and the rise of “gig economy.”

“Our mandate at Victory Square is to invest in and partner with game-changing technology companies that are redefining the markets in which they operate,” said Victory Square’s CEO, Shafin Diamond Tejani. “Howyl’s existing global talent marketplace, combined with deep industry expertise and an exceptionally strong management and technical team, will bring Victory Square into another technology-driven vertical that will experience rapid growth over the next 10 years. The Howyl team has already demonstrated a successful track record of delivering projects using a distributed workforce model, with an alpha-version platform already being used internally to service existing client work.”

“Automation, digital platforms, and other innovations are changing the fundamental nature of work,” continued Shafin Diamond Tejani. “Howyl’s ‘Capaciti’ marketplace will allow for a frictionless work environment to enable the digital support of enterprise clients, and the pipeline of global talent that services those clients.”

The addressable market for Capaciti’s initial service offering is substantial. In the U.S. alone, the digital design market is estimated at $720bn/year, with 50% of that spend flowing to outsourced professionals (https://www.comptia.org/resources/it-industry-trends-analysis).

Howyl’s 2018 focus will be to continue building its proprietary talent marketplace, while continuing to grow both its base of customers and suppliers. Howyl’s projected revenue is already on-track to exceed $3,000,000 in 2018.

“The Victory Square team is a leader in helping technology companies rapidly scale and expand into global markets, and as a result, they are the ideal partner for Howyl to facilitate our next stage of growth,” states Marc Low, CEO of Howyl Ventures Inc. “Our vision of building a decentralized project marketplace for the enterprise, which addresses the changing nature of work, requires alignment with a strategic partner that can help us build and deploy our platform around the globe. Victory Square is the ideal partner for us in this respect.”

In consultation with Victory Square portfolio company Blockchain Assembly Inc., Howyl will look to raise additional funds for the development and implementation of its blockchain-enabled platform by performing a token generation event. Victory Square is excited to expand its enterprise offerings and looks forward to building upon early success stories like Blockchain Technology Limited (BTL.V), the first publicly-traded blockchain company in Canada.

For further information about the Company, please contact:

Investor Relations Contact – Prit Singh
Email: prit@victorysquare.com
Telephone: 905-510-7636

Media Contact – Howard Blank, Director
Email: howard@victorysquare.com

Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.

ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.

FORWARD-LOOKING INFORMATION
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to the completion of the acquisition of an interest in Howyl and the timing, cost and terms thereof, the impact of the acquisition on the Company, the strategic direction of the Company, and its goal of broadening its portfolio of interests in innovative companies. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical fact contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Thursday, February 22nd, 2018 Uncategorized Comments Off on $VSQTF to Enter Definitive Agreements to Acquire 28.5% of Howyl Ventures

$PBIO Technology Could Provide Ideal Drug Delivery of Cannabinoids

February 15, 2018

  • The tide of cannabis legalization continues to rise
  • Medical cannabis market on pace to hit $56 billion in seven years
  • Company’s proprietary technology improves the bioavailability of cannabinoids

With the passage of laws permitting medicinal use of cannabis in at least 32 U.S. jurisdictions and Canada, producers of cannabinoids for medical purposes are racing to improve delivery methods for their formulations. Cannabinoids, such as cannabidiol (CBD), are hydrophobic (literally, afraid of water). In practice, this means they do not dissolve or emulsify readily in water, which may seem to pose a problem, since, by composition, the human body is more than half water. Yet, paradoxically, for a drug to be readily absorbed, it must be largely hydrophobic, yet not completely so. It must, to some extent, dissolve in water. As a result, new, patented technology from Pressure BioSciences Inc. (OTCQB: PBIO) may provide the ideal transport for CBD and other cannabinoids. PBIO’s Ultra Shear Technology (“UST”) has the capacity to develop water-soluble nanoemulsions that can be employed to improve the bioavailability of cannabinoids.

Emulsions are mixtures of two or more liquids (e.g., oils in water) that cannot be blended into each other without the addition of chemicals called emulsifiers (e.g., surfactants). Emulsions are used in multiple everyday products, including food, medical products, pharmaceuticals, nutraceuticals, cosmetics, industrial lubricants, and even cannabis oil extracts (e.g., CBD). Nanoemulsions have been shown to have improved absorption while providing higher bioavailability, greater stability and other advantages, when compared to the standard, much larger macro- and micro-emulsions.

Nanoemulsions offer an advanced mode of drug delivery that’s expected to improve the bioavailability of a wide range of active agents. These nano-sized emulsions, in which two immiscible liquids are usually combined to form a single phase by means of an emulsifying agent that combines surfactant and co-surfactant, typically have droplet sizes that fall in the 20–200 nanometer range. It would take 10 million nanometers to cover a length of one centimeter (about 0.4 inches).

Interestingly, PBIO believes that its patented UST may be able to make commercial-scale nanoemulsions that would require far less emulsifying agents than current methods, perhaps even none. Emulsifying agents are chemicals; some are natural, some are not. With consumer demands for non-additive natural products, the availability of nanoemulsions that require little or no chemical emulsifiers should be well received by consumers and manufactures alike, and rewarded by shareholders.

Late last year, PBIO announced a partnership with Phasex Corporation. The aim of the collaboration is to combine PBIO’s patented UST and Phasex’s supercritical fluid (“SCF”)-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. Phasex is a pioneer in the development of SCF-based toll processors, which are used for extracting, purifying, recrystallizing and fractionating a wide range of polymers, natural extracts and other chemicals.

Complementing Phasex’s SCF extraction technology with PBIO’s UST makes a great deal of commercial sense. Currently, there is a market for new methods of turning hydrophobic extracts into stable, water-soluble formulations. UST offers the potential to solve that problem by producing stable nanoemulsions of oil-like products in water. The range of commercial applications is extensive and includes inks, industrial lubricants, cosmetics, pharmaceuticals and nutraceuticals, as well as medically important plant oil extracts such as CBD. UST utilizes ultra-high pressure-driven fluid dynamic shear forces, combined with controlled temperatures, to engender homogenization.

Data from scientific studies indicate that nanoemulsions of nutraceuticals and pharmaceuticals may exhibit improved absorption, higher bioavailability, greater stability and lower levels of stabilizing additives (surfactants) when compared to the larger droplet sizes resulting from current emulsion processes. Because of these significant advantages, nanoemulsions are currently the focus of many research efforts worldwide. In this field, the PBIO-Phasex joint venture is poised to break new ground. Combining Phasex’s SCF extraction methodology with PBIO’s disruptive drug delivery technology may signal the genesis of an entirely new paradigm in therapeutic treatments.

The global medical marijuana market is set to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. As it expands, the demand for enabling medical technologies, such as UST, is set to rise. PBIO, it seems, is about to thrive in the brave new world of cannabis liberalization.

For more information, visit the company’s website at www.PressureBioSciences.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, February 22nd, 2018 Uncategorized Comments Off on $PBIO Technology Could Provide Ideal Drug Delivery of Cannabinoids

$CIIX Pursuing a Diversified Future in Cryptocurrency, Baijiu and Cannabis

February 22, 2018

  • Chinese investors seek cryptocurrency education as they adapt and continue to diversify portfolios with bitcoin
  • CBD Biotechnology advancing distribution of baijiu
  • CIIX planning to spin-off ChineseHempOil.com and CBD Biotechnology subsidiaries in order to focus on cryptocurrency markets

ChineseInvestors.com (OTCQB: CIIX) is an emerging leader in the adoption of cryptocurrencies and blockchain technologies. The company has been leading the way in providing financial information and education for Chinese-speaking investors in the United States and China since 1999. CEO Warren Wang believes that cryptocurrency and blockchain technologies will play a growing role in China’s future economy.

Currently, CIIX broadcasts a daily newscast titled ‘Bitcoin MultiMillionaire’ and operates www.NewCoins168.com, a free Chinese-language bitcoin education site. The company is ready to meet the challenges associated with a growing need for informed reporting and education among the rapidly emerging middle- and upper-class in China, as well as new investors. There are challenges on the horizon with the adoption of blockchain technologies (http://cnw.fm/U5Uci) that CIIX is ready to meet. Chinese investors have managed to adapt to the Beijing ban on cryptocurrency and continue to diversify their portfolios with bitcoin. CIIX is meeting the demand through innovative moves such as the recent addition of a bitcoin ATM in the lobby of its U.S. headquarters in California.

CIIX plans to focus on its new cryptocurrency division and core financial education business. Part of the process is to spin-off its CBD Biotechnology and ChineseHempOil.com subsidiaries, with plans to register them as a separate publicly traded company. This move will allow CIIX to focus more on educational services related to cryptocurrencies and blockchain technologies targeted at the Chinese public. It also offers new opportunities for its subsidiaries.

CBD Biotechnology Co. Ltd. acquired a wholesale alcohol License in China in 2017. The company has expanded its Chinese consumer division to include distribution of baijiu, a popular Chinese grain liquor, by aligning with China GuiZhou HanTai Wine, Inc. CBD Biotechnology has also partnered with Jinri Toutia (translation: Today’s Headlines) to strengthen its marketing platform. Both moves are in hope of strengthening CBD Biotechnology’s brand awareness and sustainable revenue growth.

CIIX’s goal, through subsidiary ChineseHempOil.com, is to become the leading publicly traded company targeting Chinese medicinal marijuana. The creation of an Apple App Store-approved Yelp-style app allows customers to find and recommend nearby locations for medical and recreational cannabis. The company has plans to open a retail store in San Gabriel, California, this year, and it continues to provide nutritional supplements containing CBD through its online platform at www.ChineseCBDoil.com.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Thursday, February 22nd, 2018 Uncategorized Comments Off on $CIIX Pursuing a Diversified Future in Cryptocurrency, Baijiu and Cannabis

$ETST Advances in Prosperous Cannabis Industry – NetworkNewsBreaks

January 31, 2018

  • Cannabis industry expected to reach $24.5 billion in sales within four years
  • Company expanding into Canada ahead of expected nationwide legalization
  • Medical diagnostic device set for clinical tests to validate detection of STDs

With the sunny investment disposition toward marijuana and blockchain-related industries carrying over from late 2017’s marketplace into the new year (http://nnw.fm/3Kzml), Florida-based Earth Science Tech, Inc. (OTC: ETST) is optimistic about its ability to serve the medical and recreational needs of a growing population of cannabis users. The biotechnology company has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high-grade hemp CBD oil, placed its cannabidiol (CBD) food products in retail stores throughout the country, established a non-profit foundation to help underprivileged patients use its products and acquired Quebec, Canada-based Canna Inno Laboratories Inc. in a bid to expand into that country as it prepares to legalize the recreational use of marijuana on a national basis later this year.

Earth Science Tech, Inc. announced in May 2014 that it was entering the legal cannabis and medical marijuana industry as a natural progression of its mission to deliver wellness and alternative medicine options to American consumers. In the nearly four years since, a growing number of states have legalized medicinal and recreational uses for marijuana derivatives as popular sentiment has shifted toward acceptance of the drug despite its continued classification as a controlled substance by the federal government. The revolution in Canada that is expected to result in full legalization this summer has outpaced U.S. attitudes and provided a near-neighbor alternative for U.S. businesses that continue to encounter market obstacles at home.

Variances in forecasts about the market potential for the legal cannabis industry are measured in billions of dollars nowadays; cannabis industry analysts Arcview Market Research, in partnership with BDS Analytics, predicts that the market will reach $24.5 billion in sales within the next three to four years with a 28 percent CAGR that follows on a 33 percent increase between 2016 and 2017 despite ongoing federal prohibition (http://nnw.fm/pEAM5). As this market potential grows, Earth Science Tech is working to uplist under the OTCQB’s regulations for new Tier II Regulation A+ companies, with hopes for SEC approval by March.

The proposed uplisting will underpin efforts to raise an additional $4 million in operating capital so the company can complete planned projects advancing its brand in the United States and Canada. In December, Earth Science Tech announced a CBD product revamp and brand education strategy (http://nnw.fm/3nYfW) that it expected to launch by the end of January, along with a renewed push for major donors to help its non-profit foundation and a collaboration with a start-up accelerator in Canada to help it ramp up its brand awareness.

In February, the company plans to begin a nine-month series of human clinical trials on its new CBD formulation, which is designed to decrease cravings and the negative effects of withdrawal in addicts. If the trials prove successful, the product is set to launch in 2019 as a new addition to the stable of Earth Science Tech patent-pending offerings.

“We look to hit the ground running in 2018 with all we have lined-up in the first quarter,” president, director and COO Nickolas Tabraue stated in a news release. “We have other exciting discussions that are progressing well, and we will share those once any material developments have been finalized. Our story and vision will be seen very soon and we greatly appreciate all who have believed in us since the beginning.”

Another aspect of Earth Science Tech’s mission is to develop low-cost, noninvasive home-use diagnostic tools for sexually transmitted infections and/or diseases. The company’s first medical device has been labeled MSN-2, which is set for clinical tests under an agreement with Laboratories BNK Canada to ensure the device meets regulatory requirements as part of the company’s bid to meet the specific needs of women. Earth Science Tech has already established the MSN-2 device’s ability to detect chlamydia, and it now aims to validate similar results for gonorrhea, another sexually transmitted disease that can have permanent consequences for patients if untreated. The company also plans to add testing to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. The diagnostic testing market for STDs is expected to grow to $108 billion by 2019, according to Transparency Market Research.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Wednesday, February 21st, 2018 Uncategorized Comments Off on $ETST Advances in Prosperous Cannabis Industry – NetworkNewsBreaks

$PBIO Deal with ISS Shows Potential to Enhance Drug Discovery & Development

February 21, 2018

  • The two companies entered co-marketing and distribution agreement to be implemented worldwide
  • Pressure BioSciences’ high pressure generator technology can improve optical spectroscopy accuracy and data collection with potentially far-reaching impact on drug development
  • The joint technology will be promoted to scientists all over the world and is expected to generate increased sales starting this year

A leading developer and provider of innovative high pressure-based solutions to the global life sciences industry, Pressure BioSciences, Inc. (OTCQB: PBIO) has entered a two-year agreement with ISS, Inc., a prominent designer and manufacturer of advanced scientific instruments with more than 30 years of experience in the field. Under the agreement, the two companies will join their marketing and distribution efforts worldwide, as well as their own technologies to create an advanced high pressure optical spectroscopy system that’s expected to generate significant data that could be critical to the discovery and development of new biopharmaceutical diagnostics and drugs, according to a Pressure BioSciences press release issued on February 14, 2018 (http://cnw.fm/PdX88).

Optical spectroscopy is typically used by scientists all over the world as a powerful analytical method to generate and gather information about the composition of biological molecules. The collected data have multiple applications ranging from the design of new drugs to the development of preventive strategies against certain diseases. However, with high pressure optical spectroscopy, scientists have access to a more unique and effective way to study molecular interactions instantaneously and with a better control of reversibility and irreversibility, due to the easily adjustable duration and amount of applied pressure. This can greatly improve the speed and accuracy of data collection, helping scientists better understand how biological molecules function and interact, with a significant impact on the discovery and development of improved drugs and diagnostics.

ISS is confident that, by using Pressure BioSciences’ patented and game-changing pressure cycling technology (“PCT”) with its optical cell systems instead of current manual pressure generators, scientists will be able to “visualize biochemical reactions as they are happening in the pressure cell,” as noted by ISS President Dr. Ben Barbieri in a news release. “The Pressure BioSciences pressure generators will also facilitate automated and significantly faster data collection. Such systems could potentially have a significant and far-reaching impact on drug development and other important areas of biomedical research worldwide,” he added.

“This powerful combination of technologies will be promoted to scientists worldwide by both Pressure BioSciences and ISS, with the combined system expected to drive an increase in sales this year and beyond,” commented Dr. Nate Lawrence, PBIO VP of Marketing and Sales.

The ISS Agreement is the latest in a series of acquisitions and collaborations that Pressure BioSciences has entered into over the last few months, including, most notably, the acquisition of BaroFold, Inc.’s assets in December of last year and its entry into a strategic partnership with Phasex Corporation in October 2017. The BaroFold acquisition has significantly increased the company’s intellectual property estate by eight issued patents and several others that are pending, as noted by CEO Richard T. Schumacher on a ‘Stock Day’ podcast (http://cnw.fm/JBO5o).

With Phasex, the collaboration has allowed Pressure BioSciences to enter the fast-growing nanoemulsions market, where its proprietary PCT-based Ultra Shear Technology can be used with Phasex’s Supercritical Fluid processing to generate water-soluble, fully stable nanoemulsions. Ensuring stability of nanoemulsions has been a challenge until now, but this strategic collaboration has every chance to change that, leading to the further expansion of an already large market and an increase in the number of potential nanoemulsion applications in industries ranging from pharmaceuticals, nutraceuticals, cosmetics, paints and industrial lubricants to food and even medical cannabis (e.g., CBD).

Unlike most commercially-available emulsions, which tend to be unstable and sometimes inappropriate for human use due to a high amount of surfactants required, nanoemulsions have been shown to improve absorption, enhance stability, exhibit higher bioavailability, contain reduced amounts of surfactants and present multiple other advantages. Pressure BioSciences is confident that, with its patented Ultra Shear Technology, it will be able to develop commercial-scale nanoemulsions that require less emulsifying events, or even none at all.

For more information, visit the company’s website at www.PressureBioSciences.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Wednesday, February 21st, 2018 Uncategorized Comments Off on $PBIO Deal with ISS Shows Potential to Enhance Drug Discovery & Development

$NETE Joins the Enterprise $ETH Ethereum Alliance

Prestigious Enterprise Ethereum Alliance welcomes Net Element to its network of innovative companies 

MIAMI, FL, Feb. 21, 2018  — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group, today announces that it has joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative with over 250 member companies. Net Element’s membership to the prestigious alliance is complementary to the Company’s recently announced decentralized blockchain technology solution that will enable an unlimited number of value-added services (“VAS”) and support the adoption of Ethereum in the enterprise.

The EEA seeks to augment Ethereum adoption as an enterprise-grade technology, with research and development focused on privacy, confidentiality, scalability and security.  Net Element is developing a decentralized crypto-based ecosystem to act as a framework for a number of value-added services that can connect merchants and consumers directly, via blockchain technology, while increasing the economic efficiency of all transactions conducted within the ecosystem.

Part of this initiative is the Company’s recently launched Netevia platform which delivers end-to-end multi-channel payment processing through easy-to-use APIs, point-of-sale (“POS”), e-commerce and mobile devices.  Netevia’s blockchain solution, code-named “VIA Protocol,” is currently under development and is intended to enable new billing methodologies over the blockchain as well as create dynamic service offerings such as rewards, loyalty and one-click payments.

“EEA’s rapid growth in membership mirrors the accelerating acceptance and deployment of Ethereum blockchain solutions in the global marketplace,” says Julio Faura, EEA’s chairman of the board. “The technological breadth, depth and variety of organizations coming together under the auspices of EEA to create and drive enterprise Ethereum standards bodes well for the future development of the next-generation Ethereum ecosystem.”

“We are excited to be a part of the Ethereum Alliance, which connects Fortune 500 enterprises, startups, academics and technology vendors with Ethereum subject matter experts,” comments Net Element CEO Oleg Firer. “We look forward to leveraging the EEA network as we build more value for our community by developing our blockchain ecosystem for value-added services.”

“Net Element is focused on delivering value-added solutions for our community as we develop decentralized blockchain solutions to connect merchants and consumers. Alongside leading global enterprises, such as Microsoft, Intel, JPMorgan, Samsung, ING, MasterCard, Thomson Reuters, Cisco Systems, and others, we have partnered with EEA to establish clear roadmap, robust governance model, and useful Ethereum resources.”

About The Enterprise Ethereum Alliance
The EEA is an industry-supported, not-for-profit established to build, promote, and broadly support Ethereum-based technology best practices, open standards, and open-source reference architectures. The EEA is helping to evolve Ethereum into an enterprise-grade technology, providing research and development in a range of areas, including privacy, confidentiality, scalability, and security. The EEA is also investigating hybrid architectures that span both permissioned and public Ethereum networks as well as industry-specific application layer working groups.

EEA will collectively develop open industry standards and facilitate collaboration with its member base and is open to any members of the Ethereum community who wish to participate. This open-source framework will enable the mass adoption at a depth and breadth otherwise unachievable in individual corporate silos and provide insight to the future of scalability, privacy, and confidentiality of the public Ethereum permissionless network. Further information is available at www.entethalliance.org.

About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S. it aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, our cloud based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™.  In 2017 we were recognized by South Florida Business Journal’s as one of 2016’s fastest growing technology companies. Further information is available at www.netelement.com.

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to the timing of completion of new features for the Netevia platform, whether contemplated projects and the utilization of blockchain technology will be successful, whether the addition of blockchain technology-focused payment processing solutions business will become a framework for multiple value-added services, whether the Company will be successful in expansion and growth endeavors; and even if it is successful in any or all of these endeavors, whether this will positively impact the Company or result in improved shareholder value. Additional examples of such risks and uncertainties are: (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Net Element, Inc.
1-786-923-0502
media@netelement.com
Wednesday, February 21st, 2018 Uncategorized Comments Off on $NETE Joins the Enterprise $ETH Ethereum Alliance

$VSQTF Among Five Blockchain Companies to Watch in 2018

February 21, 2018

NetworkNewsWire Editorial Coverage: Blockchain technology and cryptocurrency unarguably have the potential to alter the future of money, finance, transportation and national security. While an increasing number of blockchain plays wind their way through the investment community, Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) (VSQTF Profile) is demonstrating a particular measure of blockchain innovation potential in a wide range of industries, including payment processing, mobile gaming, and more.  Other companies seizing territory in the blockchain technology space include tech-giant IBM (NYSE: IBM), Walmart (NYSE: WMT), Visa (NYSE: V) and Hive BlockChain Technologies (TSX:HIVE.V) (OTC: HVBTF).

Why Victory Square Technologies is One to Watch

Experienced in backing new ventures, Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) finances and engages entrepreneurs, bringing them into a fold of education programs, global mentor networks, and effective distribution partnerships.

The company has corporate history in entertainment, sports, finance, energy infrastructure, healthcare and gaming, and thus can intelligently ease pathways for blockchain technologies and companies into those sectors and others.

Victory Square’s impending CAD $1.9 million investment in emerging merchant processor PayVida Solutions Inc. is just one of the company’s anchors in the blockchain space (http://nnw.fm/jVxk5).

While the acquisition of a stake in PayVida enables Victory Square to invest in payment processing, the company’s most recent investment enables a unique position in one of the highest grossing segments of the entertainment industry.

Recognizing the opportunity to leverage blockchain with in the burgeoning global gaming market, Victory Square in mid-February disclosed an agreement to acquire 100 percent of Vancouver-based V2 Games Inc. for $2 million CAD (US$1.6 million) (http://nnw.fm/mD40h).

Founded as a game development and publishing studio, V2 Games now boasts an operating history of licensing large IPs, and was the first Canadian company to license the PAC-MAN IP for a mobile game. The company’s licensing portfolio also includes Hello Kitty, the NFL and the NBA. Leveraging its success in mobile gaming, V2 Games invests its returns into other gaming companies, providing them with seed capital and expertise needed to growth their business. Recent investments include Flow, an equity crowdfunding platform for blockchain-powered games; and AR blockchain company, Shape Immersive.

The virtual nature of modern gaming is pushing the global gaming industry into overdrive. Analysts forecast that the industry will reach nearly $109 billion by 2017 (http://nnw.fm/DW28q), with the mobile gaming segment gobbling up 42 percent of the market.

The integration of blockchain-based cryptocurrencies into this burgeoning industry will likely push gaming to unprecedented heights by providing gamers with even more options, rewards and upgrades.

V2 Games’ strategy is to leverage this growth, along with Victory’s Square’s expertise in blockchain and the public markets, to offer top-tier opportunities to retail investors while facilitating new financing opportunities in the gaming industry.

Establishing Industry Roots

For Victory Square, exponential success in blockchain means embedding in and pursuing opportunities in the broader ecosystem.

In December 2017, Victory Square Technologies joined the Blockchain Investors Consortium (“BIC”), an influential group with more than $2 billion of digital assets. BIC pools member experience and expertise in shared due diligence efforts to identify investment opportunities in the most promising and disruptive blockchain-enabled companies.

The membership enabled a pathway for Victory Square Technologies to take an early-mover position in the Initial Coin Offering (“ICO”) rush via participation in Bluzelle’s (“BLZ”) early contributor round token sale (http://nnw.fm/8kxfC). With the purchase of a $250,000 allocation of BLZ tokens, Victory Square also received 25 percent more tokens for its contribution.

Victory Square also retained Bluzelle CEO Pavel Bains as a strategic advisor to help advance Victory Square’s Blockchain Assembly portfolio company, leveraging his expertise in blockchain and fintech, including ICOs and tokens.

History of Blockchain Investments

As an early investor in blockchain technologies, Victory Square has a deep background and insights to share with affiliated companies. More than three years ago, Victory Square incubated and invested in BTL Group Ltd. (TSX:BTL), the first publicly traded blockchain company (http://nnw.fm/aUcJ3) with a current market cap of over US$220 million. It has also enabled the integration of blockchain technology into the betting website FansUnite, creating a blockchain FAN token to place wagers and building a more-easily verifiable and transparent betting platform.

At FansUnite, the success of blockchain’s technology is such that Darius Eghdami, co-founder and CEO of FansUnite, said, “We are confident it will become the gold standard among sports betting sites around the world.”

Aside from sports betting, Victory Square has diversified its portfolio into VR/AR gaming, personalized health and film.

Victory Square’s track record of strategic investments not only expands its portfolio of disruptive technology investments, but builds its momentum and pace in the broader blockchain industry.

Other Notable Companies in the Blockchain Space

IBM (NYSE: IBM) has already taken a big lead in blockchain tech for supply chain management, aiming to reduce cash cycle time, increase transaction visibility, and reduce the overhead and number of cost intermediates (http://nnw.fm/ct4LZ). Customs declarations are seen as a growth market for the technology (http://nnw.fm/5cxPP), due in large part to blockchain’s ability to ensure asset transfer integrity across a company’s entire supply chain via distributed ledger authentication, a network-driven capacity hailed as the answer to the difficult, costly, time-consuming and risk-inviting practice of maintaining such records via antiquated, sole-source in-house methods.

Walmart (NYSE:WMT), in collaboration with IBM, Chinese retailer JD.com (NASDAQ:JD) and Tsinghua University National Engineering Laboratory,  recently reported the creation of a Blockchain Food Safety Alliance to improve food tracking and safety in China (http://nnw.fm/5Ip1c). In a test program, Walmart showed that the application of blockchain technology reduced the time it took to trace a grocery store’s mango supply chain back to its farm origins to two seconds from what had taken several days. While mangoes are rarely if ever lethal, each year one in 10 people fall ill globally as a result of food-borne diseases; of those, about 420,000 die. The blockchain-enabled ability to rapidly trace bad food to the source and eliminate it from the food chain will mark an important advance in food safety.

Visa (NYSE:V) began testing a new cross-border payments solution dubbed B2B Connect in late January, tying in with financial institutions such as UnionBank, The Bank of Tokyo-Mitsubishi UFJ (NYSE:MTU), and Korea-based Shinhan Financial Group. Visa said B2B Connect eliminates friction for cross-border transactions by using distributed ledger (blockchain) technology to enhance the speed, security and reliability of transactions. Other companies involved in the Visa BTB payment effort include blockchain firm Blocko, the Japan Bank Consortium and Woori Bank.

Hive BlockChain Technologies (HIVE.V, HVBTF), which listed on the Toronto Stock Exchange last September, plans to build bridges from the blockchain sector to traditional capital markets. HIVE has partnered with Genesis Mining Ltd., touted as the world’s largest cloud-based blockchain and cryptocurrency mining company, to build the next generation of blockchain infrastructure. HIVE owns state-of-the-art GPU-based digital currency mining facilities in Iceland that produce newly minted virgin digital currency like Ethereum around the clock, and is in the midst of a major expansion of operations into Sweden.

The Next Act

The rapid emergence of blockchain technology and its acceptance in multiple marketplaces present a possibility of a once-in-a-generation investment opportunities in a transformational technology, somewhat akin to the early dot-com days.  The words “creative destruction” or “disruptive technology” hardly do credit to the beneficial upheavals pending in finance, payment processing, transportation and other industries as blockchain platforms become pervasive.

Especially well-positioned will be those tested investor-practitioners, such as Victory Square Technologies, who have the added perspective of industry experience outside of software to anticipate in which sectors blockchain platforms will be especially accepted, useful or profitable.

One thing is certain, there will be plenty of room for winners in the blockchain space. The market for blockchain-related products and services is expected to reach $7.7 billion in 2022, up from $242 million in 2017, an astonishing 32-fold increase, reports researcher Markets & Markets.

That huge increase in blockchain-related enterprise is expected in the next five years. But, as with the Internet, the real growth and shape of blockchain applications will likely be decades in the making.

For more information on Victory Square Technologies Inc. please visit: Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) or please read: Blockchain Revolution Triggers Massive Profit Opportunity

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Wednesday, February 21st, 2018 Uncategorized Comments Off on $VSQTF Among Five Blockchain Companies to Watch in 2018

$CIIX Diversifies Methods of Reaching Global Chinese-speaking Audience

February 12, 2018

  • CIIX diversifies methods of reaching its global Chinese-speaking audience, with projects ranging from a daily video broadcast from the NYSE on cryptocurrencies to the development of a new social media mobile app for the cannabis industry
  • Company’s new mobile app expected to be the first Chinese-language app offering reviews and discussion of cannabis products
  • ‘Bitcoin MultiMillionaire’ is the company’s daily video broadcast from the NYSE prepared for its unique and expansive audience

ChineseInvestors.com, Inc. (OTCQB: CIIX) is reaching out to the global Chinese-speaking community through both daily video broadcasts on cryptocurrencies and, soon, a new mobile app focused on reviews and discussion of cannabis products. CIIX is involved in both product areas. The company is a diverse educational and consulting firm targeting the Chinese-speaking community in both China and the U.S.

In cryptocurrencies such as bitcoin, the company is active in educational activities, produces a daily video broadcast from the NYSE titled ‘Bitcoin MultiMillionaire’ and hosts a Bitcoin ATM in the lobby of its San Gabriel, California, headquarters.

In cannabis, CIIX has ChineseHempOil.com, Inc., a wholly-owned subsidiary. That company markets, both online and through traditional retail, a line of hemp-based health products. The line consists of premium private label oil made from non-industrial hemp, manufactured using a CO2 extraction process.

The company’s new cannabis mobile app, focused on marijuana reaching social media, was noted in the January editions of both the Tiny Gems Newsletter (http://cnw.fm/hDX1G) and the Serious Traders Newsletter (http://cnw.fm/4qtlF).

While the company reaches out to its audience in new ways, its subsidiary, CBD Biotechnology Co., Ltd., is also expanding its line of luxury skincare products (http://cnw.fm/Eauh2). Its products have been approved for sale in China by the China Food and Drug Administration (CFDA). CIIX has scheduled the launch of four new hemp-infused products and a breakthrough magnetic mask. Additionally, as part of its strategic plan to boost revenues, it has aligned with China GuiZhou HanTai Wine, Inc. (http://cnw.fm/5krVp) to begin baijiu liquor sales. Baijiu is a grain-based Chinese alcoholic beverage.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Wednesday, February 21st, 2018 Uncategorized Comments Off on $CIIX Diversifies Methods of Reaching Global Chinese-speaking Audience

$STLHF Rapid Extraction Process Reinventing Lithium Industry

The lithium industry needs to modernize and upgrade its extraction processes if it is going to keep up with escalating market demand for battery grade lithium.  And as Bloomberg reports, the world needs a lot of lithium – fast.

The industry needs a modernizing evolution because extraction methods border on archaic – the process was designed around the 1960’s, and it hasn’t been advanced because the demand for battery-grade lithium materials has only really taken off in the last few years.

Currently Albemarle (NYSE: ALB) is the only company producing lithium inside the United States – in Nevada’s Clayton Valley. Companies like  Chilean multinational Sociedad Química y Minera (NYSE: SQM), Nemaska Lithium (NMX. TO) and Lithium Americas (NYSE: LAC) are scrambling to speed up processes.

A main reason for Tesla’s (NASDAQ: TSLA) existence is that Lithium ion batteries have a high-enough charge capacity to make Battery Electric Vehicles viable.

Headquartered in Vancouver, the junior mining company capital of the world, Standard Lithium (TSX.V:SLL) (OTC:STLHF) is building an impressive portfolio of brownfield U.S. based lithium brine assets,  fast-tracking a path to production and linking lithium carbonate to global markets ­from its project sites deep in the investor heartland of the United States.

CEO Robert Mintak and President Dr. Andrew Robinson partnered to launch Standard Lithium last year. The pair formerly founded and operated Pure Energy Minerals, recognized as the top mining company in the 2016 TSX Venture 50.

“Batteries are now 40 per cent of the use of lithium worldwide – and it’s going to be approaching 60% by 2020,” Mintak said. “The industry is now looking for an evolution. It’s at a tipping point where brine producers need to step up their game if they’re going to compete with hard rock producers to bring projects online quickly.”

“The industry has been operating, basically, with mid-20th century technology for the past 50 plus years. Over half of the lithium can be lost when it is being extracted from the ground because the process is so rudimentary. A lot of companies are chasing after modern processing.”

In January, Standard entered into an agreement with Canaccord Genuity, as sole bookrunner and lead underwriter on behalf of a syndicate of underwriters. The Underwriters agreed to purchase 9,530,000 units of the Company for $20 million. Standard also signed an agreement with TETRA Technologies (NYSE: TTI) for up to 33,000 acres of brine leases in a key production fairway in Southern Arkansas.

Standard has two Lithium brine projects: Bristol Dry Lake in California’s Mojave Desert, and the Smackover Project in Southern Arkansas. At both sites, but especially in Arkansas, the company is set to revolutionize the Lithium Industry by applying modern processing methodologies with the goal of fast-tracking production – bringing the lithium recovery from brine process time down from as long as two years to an astonishing 72 hours.

The location of the Smackover projet is ideal, the agreements that Standard has signed allows them immediate access to brine, and the Arkansas project sits in close proximity to key infrastructure already in place.  The site is close to the ports of the Gulf of Mexico.

Until now, no one has built a new lithium project using modern extraction methods.

Standard Lithium is demonstrating faster production through its immediate access to thousands of litres of brine with good lithium concentration. This modernized, 72-hour selected extraction process is a game changer, Mintak said.

“In the same way that shale, or unconventional oil, affected the oil and gas industry, a modern, selective extraction process will reinvent the way people look at lithium projects,” he said.

Mintak says the best place in the world to demonstrate that is Arkansas. “We have everything we need; we have brine that is rich in lithium — it can be produced in amazing volumes.”

“The demand for lithium is real. The world is going to need a lot more lithium, and there are a lot of companies chasing after it, but you need to be able to show a path to production – and a fast-track to production,” Mintak said.  “There are a lot of companies chasing after modernizing the Lithium extraction process. The smart ones are looking to go in as few steps from raw brine to a battery-grade lithium material.”

“Generally exploration companies chase after grade all they want – but lithium projects these are chemical processes facilities, you need manpower, infrastructure, re-agents and water to name a few if aim to produce high-quality, high- margin materails that the end user is going to require,” Mintak said.

Standard is pioneering a range of new technologies, and in addition to aligning with existing permitted operators like Tetra, Standard is working with  a range of  technology partners to apply the right process technology appropriate to the  project.

“We knew the only significant, large-scale opportunity in North America where we could execute our business model was in Arkansas. “We recognized that we couldn’t secure a large land position by ourselves because the mineral claims reside on private property, so we built a great relationship with an operator there, and that relationship has allowed us to turn Arkansas into arguably the biggest opportunity in the Lithium space right now.”

“It is the best showcase in the world for a modern lithium process to be staged.”

Infrastructure exists on the Smackover site that doesn’t exist on other Lithium sites in remote locations, such as high-altitude sites in South America.  At the Arkansas site, producers have been extracting for decades, with billions and billions of barrels of brine successfully pulled out and put back into the basin.

“The infrastructure is amazing, we have a highly trained workforce of brine handlers, and we’ve put together a really strong team of technical engineers who are very familiar with the chemistry process required – extraction experts,” Mintak said.  “We’ve aligned ourselves with the current operators in Southern Arkansas to manage to secure the only large land lease available.”

Mintak believes that this  is the only available chunk of brine leases that producers can access now. It could take years for competitors to try to piece together a land package.

Standard also signed an agreement to build a pilot plant adjacent to one of the existing brine processing chemical facilities in Southern Arkansas, where they will be able to tie into an existing pipeline, gain access to the existing brine supply, and work inside a permitted facility. And for the initial demonstration pilot plant stage, brine will also be shipped from Standard’s California site to Arkansas by rail car enabling the company to run both projects through the same test facility.

“We’ve got the perfect alignment, with the agreements and projects that we have secured, to demonstrate and build a US lithium asset utilizing a modern process,” Mintak said. “While other companies are chasing around, saying they are working on around trying to do it, we have access to all the elements required. It’s already underway, we are working on this everyday. And we’re going to build upon it.”

COMPARABLES:

Albemarle (NYSE: ALB)

Albemarle Corporation globally develops, manufactures, and markets engineered specialty chemicals, with project sites across the United States, and in South America, the Middle East, Africa and Asia. The company is currently producing lithium from brines in Nevada, producing over 6,000 tonnes of lithium carbonate per year from its Silver Peak operations. Albermarle announced that it has developed a technology that can increase production up to 125,000 tons of lithium carbonate equivalent without additional brine pumping and is expected to increase production to 80,000 tons a year by 2020.

Nemaska Lithium Inc. (TSX: NMX) (OTCQX: NMKEF)

Nemaska engages in the exploration and evaluation of lithium hard rock mining properties in Canada. Its Whabouchi property consists of 33 claims covering an area of 1,716 hectares located in the Eeyou Istchee/James Bay area of Quebec; and its Sirmac property, comprises 24 mining claims covering an area of 1,101 hectares located to the north-west of Chibougamau.

Lithium Americas (TSX: LAC) (NYSE: LAC)

Lithium Americas, together with Sociedad Quimica y Minera de Chile S.A. (“SQM”), is developing the Cauchari-Olaroz lithium project, located in the Province of Jujuy, Argentina, through its 50% interest in Minera Exar S.A. In addition, Lithium Americas owns 100% of the Lithium Nevada project (formerly Kings Valley project), and RheoMinerals Inc., a supplier of rheology modifiers for oil-based drilling fluids, coatings, and specialty chemicals.

Tesla Inc.  (NASDAQ: TSLA)

Tesla, Inc. (formerly Tesla Motors) specializes in electric automotives, energy storage and solar panel manufacturing. Founded in 2003 by Elon Musk, the company specializes in electric cars, lithium-ion battery energy storage, and residential photovoltaic panels.Tesla also sells the Tesla Powerwall ad Powerpack batteries, solar panels and solar roof tiles. Tesla’s Model S was the world’s best-selling plug-in electric car in 2015 and 2016.

Wednesday, February 21st, 2018 Uncategorized Comments Off on $STLHF Rapid Extraction Process Reinventing Lithium Industry

$ONTX Two Presentations at 2018 American Chemical Society

  • Product stability studies for rigosertib, a Phase 3 clinical stage product in development for Myelodysplastic Syndromes (MDS)
  • Discovery of a novel kinase inhibitor, ON 150030, a Type 1 inhibitor of FLT3 and Src for relapsed and refractory Acute Myeloid Leukemia (AML)

NEWTOWN, Pa., Feb. 20, 2018 — Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company’s scientists, and collaborators from the Mount Sinai School of Medicine, will present two abstracts at the American Chemical Society National Meeting & Expo. The meeting is being held in New Orleans, LA, on March 18-22, 2018.

The first abstract relates to the analysis of stability of the clinical product during storage and describes the synthesis and characterization of a de-sulfonylated product of rigosertib, Onconova’s lead phase 3 stage clinical candidate. The second abstract describes a new chemical entity ON 150030, which is a type 1 novel pre-clinical stage inhibitor of FLT3 and Src pathways, believed to be important for targeted therapy of relapsed and refractory AML.

Details for the poster presentations are listed below.

Title: Synthesis and characterization of de-sulfonylated product of rigosertib, a late phase III clinical candidate

Date: 18th March, 2018

Presentation Time: 7.00-9.00 PM CDT

Presenter: Dr. M.V. Ramana Reddy & Dr. Muralidhar Mallireddigari

Location: Ernest N. Morial Convention Center, Hall E.

Title: Discovery of a novel kinase inhibitor ON 150030, a type 1 inhibitor for relapsed and refractory AML

Date: 18th March, 2018

Presentation Time: 7.00-9.00 PM CDT

Presenter: Dr. M.V. Ramana Reddy

Location: Ernest N. Morial Convention Center, Hall E.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS).  Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule agent, which we believe blocks cellular signaling by targeting RAS effector pathways.  Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.  Onconova has three product candidates in the clinical stage and several pre-clinical programs.  Advanced clinical trials with the Company’s lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.  For more information, please visit http://www.onconova.com.

About IV Rigosertib

The intravenous form of rigosertib has been employed in Phase 1, 2, and 3 clinical trials involving more than 800 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with higher-risk MDS, after failure of hypomethylating agent, or HMA, therapy.

About INSPIRE

The INternational Study of Phase III IV RigosErtib, or INSPIRE, was finalized following guidance received from the  U.S. Food and Drug Administration and European Medicines Agency and derives from the findings of the ONTIME Phase 3 trial.  INSPIRE is a multi-center, randomized controlled study to assess the efficacy and safety of IV rigosertib in HR-MDS patients who had progressed on, failed to respond to, or relapsed after previous treatment with an HMA within the first 9 months or nine cycles over the course of one year after initiation of HMA treatment.  This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines.  Following interim analysis in early 2018, the independent Data Monitoring Committee recommended that the trial continue with an expansion in enrollment to 360 patients based on a pre-planned sample size re-estimation.  Patients are randomized at a 2:1 ratio into two treatment arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.  The primary endpoint of INSPIRE is overall survival. Full details of the INSPIRE trial, such as inclusion and exclusion criteria, as well as secondary endpoints, can be found on clinicaltrials.gov (NCT02562443).

About Oral Rigosertib

The oral form of rigosertib was developed to provide more convenient dosing for use where the duration of treatment may extend to multiple years. This dosage form may also support many combination therapy modalities.  To date, 368 patients have been treated with the oral formulation of rigosertib.  Initial studies with single-agent oral rigosertib were conducted in hematological malignancies, lower-risk MDS, and solid tumors.  Combination therapy of oral rigosertib with azacitidine and chemoradiotherapy has also been explored.  Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.  A Phase 1/2 trial of the combination therapy has been fully enrolled and the preliminary results were presented in 2016. This novel combination is the subject of an issued US patent with earliest expiration in 2028.

Forward Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova Therapeutics, Inc.’s expectations regarding the INSPIRE Trial. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including Onconova’s ability to continue as a going concern, the need for additional financing and current plans and future needs to scale back operations if adequate financing is not obtained, the success and timing of Onconova’s clinical trials and regulatory approval of protocols, and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

General Contact

http://www.onconova.com/contact/

Investor Relations Contact

Katja Buhrer, Affinity Growth Advisors on behalf of Onconova Therapeutics

Katja.Buhrer@affinitygrowth.com / (212) 661-7004

Tuesday, February 20th, 2018 Uncategorized Comments Off on $ONTX Two Presentations at 2018 American Chemical Society

$CVRS Receives FDA Clearance for CorPath in PVI

Expanded Indication Extends Robotic Precision to Broader Patient Base with Vascular Disease

Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) procedures.

The advanced CorPath GRX System broadens the capabilities of the CorPath robotic technology platform from exclusively treating coronary artery disease (CAD) to include peripheral artery disease (PAD). It is estimated that 8.5 million people in the United States are living with PAD, a disease of blood vessels outside the heart that commonly affects arteries carrying blood to the lower extremities. In 2017, peripheral procedures were estimated to be a $3.4 billion market, and it is estimated that by 2020, one million PAD procedures will be performed annually in the U.S.1,2

“My colleagues and I have seen first-hand how CorPath GRX can overcome the challenges of manual PCI and I am excited to apply the capabilities of robotics to effectively treat PAD patients,” said Alan Lumsden, M.D., Chief of the Department of Cardiovascular Surgery at Houston Methodist Hospital. “As a training site for future robotic interventionalists, I look forward to teaching these techniques to further enhance the quality of care for patients with both CAD and PAD.”

“CorPath GRX enables me to provide transformational treatment options to my patients suffering from PAD,” said Joseph Ricotta, M.D., Medical Director of Vascular Surgery and Endovascular Therapy, Tenet Healthcare, Professor of Surgery, Charles E Schmidt College of Medicine, FAU. “As a long-time adopter of robotics, I am passionate about the opportunity this technology presents to advance endovascular care while providing a safer work environment for healthcare providers.”

Mark Toland, President and Chief Executive Officer of Corindus, stated, “The ability to treat patients with PAD using CorPath GRX is a significant step for Corindus as we expand the usage of our technology beyond PCI. The new indication aligns with our objective to provide more patients access to the benefits of precise robotic treatment while protecting healthcare professionals from harmful radiation during lengthy PVI procedures. We will continue to improve upon our technology platform with a keen focus on providing physicians the tools necessary to enhance patient care across the spectrum of interventional medicine.”

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company’s CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit “One Stent Program.” For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward-Looking Statements

Statements made in this release that are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.

Examples of such statements include statements relating to Corindus’ ability to successfully expand the usage of the CorPath GRX System for peripheral artery disease (PAD) and the anticipated size of the PAD market.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus’ website at http://www.corindus.com.

______________________

1 Millennium Research Group 2013 Peripheral Vascular Devices US 2013 Market Analysis RPUS 11PV14 p 98.

2 cdc.gov/PAD.

 

Corindus Vascular Robotics, Inc.
Media Contacts:
Kate Stanton, 508-653-3335 Ext. 200
kate.stanton@corindus.com
or
Investor Contact:
Lynn Pieper Lewis, 415-937-5402
ir@corindus.com

Tuesday, February 20th, 2018 Uncategorized Comments Off on $CVRS Receives FDA Clearance for CorPath in PVI

$VYGR & $ABBV Announce Global Strategic Alzheimer’s Collaboration

Collaboration to include development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau Voyager to receive $69 million upfront payment and potentially up to $155 million in preclinical and Phase 1 option payments as well as development and regulatory milestone payments and royalties

NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Feb. 20, 2018 — AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer’s disease and other neurodegenerative diseases. This collaboration combines AbbVie’s monoclonal antibody expertise, global clinical development and commercial capabilities with Voyager’s gene therapy platform and expertise that enables generating adeno-associated viral (AAV) vectors for the treatment of neurodegenerative diseases.

In healthy individuals, tau is an abundant protein in the brain that promotes cellular stability and function. In the diseased brain, altered tau accumulates, resulting in impaired brain function and neuronal cell loss.  The progressive spread of abnormal tau in the brain closely correlates with progressive neurodegeneration and symptom severity.  However, one of the current limitations with the use of weekly or biweekly infusions of biologic therapies for neurodegenerative diseases is that only a small amount of drug is able to make its way into the brain. This collaboration seeks to develop a potential one-time treatment using Voyager’s gene therapy platform to reduce tau pathology through the delivery of an AAV vector antibody that encodes the genetic instructions to produce anti-tau antibodies within the brain.

“AbbVie is focused on developing treatments to meet the crushing public health crisis presented by Alzheimer’s and other neurodegenerative diseases,” said Jim Sullivan, Ph.D., vice president, pharmaceutical discovery, AbbVie. “Voyager’s vectorized antibody platform presents an innovative approach to addressing challenges in treating neurological disorders associated with the administration of biologic therapies. This collaboration has the potential to address the needs of patients who live with conditions such as Alzheimer’s disease, progressive supranuclear palsy and frontotemporal dementia.”

“Combining AbbVie’s leadership and deep expertise in monoclonal antibody discovery, development and commercialization and our ability to vectorize monoclonal antibodies is a natural fit, and we are very pleased to collaborate with AbbVie to advance this strategy towards the clinic in an effort to bring innovative treatments to patients,” said Steven Paul, M.D., president and chief executive officer of Voyager. “This collaboration also represents an important advance in our strategy to leverage our AAV gene therapy platform and programs through partnerships with biopharmaceutical companies that bring complementary expertise and capabilities, in addition to capital.”

Details of the collaboration and financial terms

Under the terms of the collaboration and option agreement, Voyager will perform research and preclinical development of vectorized antibodies directed against tau, after which AbbVie may select one or more vectorized antibodies to proceed into IND-enabling studies and clinical development.  Voyager will be responsible for the research, IND-enabling and Phase 1 studies activities and costs. Following completion of Phase 1 clinical development, AbbVie has an option to license the vectorized tau antibody program and would then lead further clinical development and global commercialization for tauopathies, including Alzheimer’s disease and other neurodegenerative diseases. Voyager has an option to share in the costs of clinical development for higher royalty rates.

Voyager will receive an upfront cash payment of $69 million as well as up to $155 million in potential preclinical and Phase 1 option payments. In addition, Voyager is eligible to receive up to $895 million in development and regulatory milestones for each vectorized tau antibody compound and is eligible to receive tiered royalties on the global commercial net sales of the vectorized antibodies for tauopathies, including Alzheimer’s disease and other neurodegenerative diseases.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience.  In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, with AbbVie, and the University of Massachusetts Medical School.  Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.

Forward-Looking Statements: AbbVie

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2017 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Forward-Looking Statements: Voyager

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the potential benefits and future operation of the option and collaboration agreement with AbbVie, including any potential future payments thereunder, the initiation, timing, progress and reporting of results of its preclinical programs and clinical trials and its research and development programs, its ability to advance its AAV-based gene therapies into, and successfully initiate, enroll and complete, clinical trials, the potential clinical utility of its product candidates, its ability to continue to develop its product engine, its ability to develop manufacturing capability for its products, its ability to add new programs to its pipeline, its ability to enter into new partnerships or collaborations, its expected cash, cash equivalents and marketable debt securities at the end of a fiscal period and anticipation for how long expected cash, cash equivalents and marketable debt securities will last, and the timing or likelihood of its regulatory filings and approvals, are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected.  Such risks and uncertainties include, among others, those related to the initiation and conduct of preclinical studies and clinical trials, the availability of data from clinical trials and the expectations for regulatory submissions and approvals; the continued development of the product engine; Voyager’s scientific approach and general development progress; the availability or commercial potential of Voyager’s product candidates; the sufficiency of cash resources; and need for additional financing. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made.  Voyager undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Tuesday, February 20th, 2018 Uncategorized Comments Off on $VYGR & $ABBV Announce Global Strategic Alzheimer’s Collaboration

$STLHF Provides California Lithium Exploration Update

VANCOUVER, British Columbia, Feb. 20, 2018 — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) is pleased to provide an update of the exploration program that is in full swing at the Company’s California Lithium Properties.  The Company and their drilling contractors have now completed six exploration boreholes across the Bristol Dry Lake Project area, and three of the exploration holes have had temporary sampling casing installed so that high quality lithium brine samples can be collected from the extensive lithium brine-bearing aquifers.  The temporary PVC casing also allows for down-hole geophysics to be completed to collect additional geological and hydrogeological data.  Drilling of an observation well is currently ongoing, and once completed, will allow for robust pumping tests to be performed at the Project.  An additional exploration well and observation well are already permitted, and the Company is awaiting final confirmation to allow an additional, deeper exploration borehole to be drilled on Patented claims owned by Tetra Technologies Inc.  Detailed lithium brine analyses will be issued once final, representative brine samples have been taken and cross-checked with all QA/QC to ensure quality.  All data gathered from the Bristol Dry Lake Project will be used to advance the maiden resource estimate, expected towards the end of Q2 2018.

The Company has also confirmed that a large-scale, detailed gravity geophysical survey is scheduled to be performed on the Cadiz Dry Lake Lithium Property, commencing on February 21st, 2018.  The survey has been designed to tie into historical gravity survey work completed in the Cadiz Dry Lake area by the USGS, and will allow the thickness and extent of the deep infilled basin to be properly defined.  Active brine harvesting from relatively shallow wells is ongoing in the Cadiz Dry Lake area, and Standard Lithium’s technical team will commence a full sampling program from this active well field in the next 2-3 weeks.

Quality Assurance

Raymond Spanjers, Certified Professional Geologist (SME No. 3041730), is a qualified person as defined by NI 43-101, and has supervised the preparation of the scientific and technical information that forms the basis for this news release.  Mr. Spanjers is not independent of the Company as he is an officer in his role as Vice President, Exploration and Development.

About Standard Lithium Ltd.

Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic US brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills.  The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities.  The Company is also commencing resource evaluation on up to 33,000 acres of brine leases located in the Smackover Formation.

Standard Lithium is listed on the TSX Venture under the trading symbol “SLL”; quoted on the OTCQX under the symbol “STLHF”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at www.standardlithium.com.

For further information, contact Anthony Alvaro at (604) 240 4793

On behalf of the Board,

Standard Lithium Ltd.

Robert Mintak, CEO & Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information.  These forward-looking statements or information may relate to future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information.  Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties.  Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements.  The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

Readers are cautioned that a “Qualified Person” (as that term is defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects) has not done sufficient work to specify any mineral resource or reserve on the Properties.

Tuesday, February 20th, 2018 Uncategorized Comments Off on $STLHF Provides California Lithium Exploration Update

$DJACF Hiku Brands Awarded Prized Retail Cannabis License In Manitoba

Hiku Brands is one of only four proposals selected to operate cannabis retail stores in Manitoba as part of world’s first RFP process for federally legal cannabis retail

TORONTO, Feb. 16, 2018 – Hiku Brands Company Ltd. (“Hiku” or the “Company“) (CSE:HIKU), is pleased to announce that its wholly-owned subsidiary, Tokyo Smoke, with participation by BOBHQ, has been conditionally awarded one of four master retail licenses (the “License“) in Manitoba’s highly competitive Request for Proposal (“RFP“) process for the right to operate retail cannabis stores. The License gives Tokyo Smoke the ability to operate legal retail cannabis stores and an online cannabis sales platform in Manitoba. This represents a significant milestone for Hiku and BOBHQ as one of only four successful entities selected in a highly competitive process.

Hiku is excited to bring its award winning retail experience to Manitoba and Manitoba cannabis consumers. The Company commends the leadership shown by the Province of Manitoba in setting up a competitive, privatized cannabis retail system to ensure the responsible management of cannabis distribution and sales within the province ahead of the anticipated adult-use legalization date of Summer 2018.

“We are honoured to be selected as one of four companies to operate retail cannabis stores in Manitoba“, said Alan Gertner, CEO of Hiku. “This achievement is a validation of our business model and vision of creating an unsurpassed retail experience for cannabis consumers. It is also a tribute to the hard work and dedication of our team and consultants — BOBHQ and 4Front Advisors — who helped us achieve this milestone. We look forward to participating in future licensing processes across the country to grow our national retail footprint and bring our unique retail experience to more Canadians.”

“We are thrilled to have been awarded one of four licenses in our home province of Manitoba alongside our valued partners at Hiku”, said BOBHQ co-founder Robert Ritchot. “We have the utmost confidence in our ability to provide our community with an industry-leading retail experience, while closely adhering to both Provincial and Federal legislation.”

As a retail cannabis organization, Tokyo Smoke will also participate in and contribute to social responsibility programs to provide comprehensive cannabis education to retail cannabis store customers and raise awareness of the social responsibility that comes with adult cannabis use. The Company is fully supportive of the Manitoba government’s clear policy initiatives as it relates to cannabis retail, including, social responsibility, education, protecting children and youth and preventing diversion of product to the black market.

About Hiku
Hiku is focused on building a portfolio of iconic, engaging cannabis brands, immersive retail experiences and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA’s ACMPR licensed grow, and Van der Pop’s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

DOJA Cannabis, Hiku’s wholly-owned subsidiary, is a federally licensed producer of craft cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“).  DOJA owns and operates two production facilities in the heart of British Columbia’s Okanagan Valley. The Company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

About BOBHQ
BOBHQ, a division of Humble & Fume, is a leading North American distributor of smoke shop and counterculture products with many decades of experience. With retail locations in Manitoba and distribution facilities in Canada and across the U.S., the company is able to efficiently distribute over 10,000 different products to thousands of customers throughout North America and abroad.

Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include the Company’s expectation that adult-use legalization of cannabis will occur in the of Summer 2018. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

Friday, February 16th, 2018 Uncategorized Comments Off on $DJACF Hiku Brands Awarded Prized Retail Cannabis License In Manitoba